



National Cancer Institutes in Florida

Ron DeSantis, Governor

Scott A. Rivkees, MD
Surgeon General and Secretary of Health

Three Year Report to the Cancer Control and Research Advisory Council

July 1, 2020

Table of Contents

Background.....	2
Cancer in Florida.....	Error! Bookmark not defined.
Federal Funding Awarded to Florida Institutions for cancer-related research	16
The Florida Academic Cancer Center Alliance (FACCA),.....	20
Attachment 1: Collaborative Publications	37
Attachment 2: Agendas for the following completed meetings and retreats.....	61

Background

Cancer is the second leading cause of death in the United States and Florida. Cancer mortality rates reflect the health and well-being of the population as well as the quality of the health care available. Cancer mortality information is used by local governments and organizations to identify areas in need and direct available resources.


The Florida Consortium of National Cancer Institute (NCI) Centers Program, section 381.915, Florida Statutes, was established to enhance the quality and competitiveness of cancer care in this state, further a statewide biomedical research strategy directly responsive to the health needs of Florida's citizens and capitalize on the potential educational opportunities available to students. The Department of Health (Department) makes payments to Florida-based cancer centers, recognized as NCI-Designated Cancer Centers or NCI-Designated Comprehensive Care Centers.

This report is required for submission to the Cancer Control and Research Advisory Council (CCRAB) by July 1, 2020. Further, this report is based on the statutory language that directs beginning July 1, 2020, and every three years thereafter, the Department, in conjunction with participating cancer centers, shall submit a report to the CCRAB on specific metrics relating to cancer mortality and external funding for cancer-related research in the state. If a cancer center does not endorse this report or produce an equivalent independent report, the cancer center shall be suspended from the program for one year. The report must include:

1. An analysis of trending age-adjusted cancer mortality rates in the state, which must include, at a minimum, overall age-adjusted mortality rates for cancer statewide and age-adjusted mortality rates by age group, geographic region and type of cancer, which must include, at a minimum:
 - Lung cancer
 - Pancreatic cancer
 - Sarcoma
 - Melanoma
 - Leukemia and myelodysplastic syndromes
 - Brain cancer
2. Information on trends in overall federal funding, broken down by institutional source, for cancer-related research in the state.
3. Collaborative efforts focusing on grants and interinstitutional agreements among participating cancer centers, a comparison of collaborative grants in proportion to the grant totals for each cancer center, a catalogue of retreats and progress seed grants using state funds and targets for collaboration in the future and reports on progress regarding such targets where appropriate.

Cancer in Florida

Florida has the second highest cancer burden in the nation. Some common types of cancers can be attributed to lifestyles and lack of health care access. Overall, the death rates of cancer have slightly decreased over the past 20 years in Florida. In 2016, the most common types of newly diagnosed cancers in Florida were lung, prostate, breast, colorectal, melanoma and bladder cancer.




*Florida Charts

An Analysis of Trending Age-Adjusted Cancer Mortality Rates in Florida:

Lung cancer is a disease which consists of uncontrolled cell growth in tissues of the lung. This growth may lead to metastasis, which is the invasion of cancer cells into adjacent tissue and infiltration beyond the lungs. The vast majority of primary lung cancers are carcinomas of the lung, derived from epithelial cells. The most common cause of lung cancer is long-term exposure to tobacco smoke. The occurrence of lung cancer in nonsmokers, who account for as many as 15% of cases, is often attributed to a combination of genetic factors, radon gas, asbestos and air pollution including secondhand smoke.

Lung cancer death rates have steadily declined over the last 20 years in the state of Florida. The death rate from lung cancer is significantly greater among adults over the age of 40 with the highest death rate in the 65 and older population.




*Florida Charts

The highest death rates from lung cancer occur in rural counties and are concentrated in the Florida Panhandle. Higher death rates are, in part, attributable to decreased access to prevention services, diagnostics and treatment.


Lung Cancer Crude Death Rate, Single Year Rates by Age Group, Per 100,000, 2010-2018				
Years	0-19 Years of Age	20-39 Years of Age	40-64 Years of Age	65+ Years of Age
2018	0.0	0.5	38.9	205.2
2017	0.0	0.5	40.7	211.1
2016	0.0	0.5	41.4	214.4
2015	0.0	0.6	46.3	234.1
2014	0.0	0.4	43.6	241.7
2013	0.0	0.4	47.6	248.9
2012	0.0	0.6	47.1	258.9
2011	0.1	0.5	47.0	257.2
2010	0.0	0.5	48.5	264.1

Lung Cancer Age-Adjusted Death Rate, Single Year Rates Per 100,000, 2010-2018	
Years	Rate
2018	35.7
2017	37.0
2016	37.6
2015	41.3
2014	41.3
2013	43.7
2012	45.3
2011	45.7
2010	46.2



*Florida Charts

Pancreatic cancer is a disease in which malignant (cancerous) cells form in the tissues of the pancreas. The pancreas is a gland located behind the stomach and in front of the spine. The pancreas produces digestive juices and hormones that regulate blood sugar. Cells called exocrine pancreas cells produce the digestive juices, while cells called endocrine pancreas cells produce the hormone. The majority of pancreatic cancers start in the exocrine glands.




*Florida Charts

High death rates due to pancreatic cancer have been consistently observed the last twenty years and are widespread in Florida. There is no specific region of concentration. There is an increased death rate in some rural counties.


Pancreatic Cancer Crude Death Rate, Single Year Rates by Age Group, Per 100,000, 2010-2018				
Years	0-19 Years of Age	20-39 Years of Age	40-64 Years of Age	65+ Years of Age
2018	0.0	0.2	11.1	62.5
2017	0.0	0.3	10.8	62.1
2016	0.0	0.2	12.0	63.2
2015	0.0	0.2	11.0	62.8
2014	0.0	0.1	10.3	62.1
2013	0.0	0.2	9.8	60.4
2012	0.0	0.2	11.1	61.0
2011	0.0	0.3	10.1	59.9
2010	0.0	0.2	10.4	59.4

Pancreatic Cancer Age-Adjusted Death Rate, Single Year Rates, Per 100,000, 2010-2018	
Years	Rate
2018	10.8
2017	10.7
2016	11.2
2015	10.8
2014	10.4
2013	10.2
2012	10.7
2011	10.4
2010	10.3



*Florida Charts


Melanoma is a malignant tumor of melanocytes. Such cells are found predominantly in skin but are also found in the bowel and the eye (see uveal melanoma). Melanoma is one of the less common types of skin cancer but causes the majority (75%) of skin cancer related deaths. Melanocytes are normally present in skin, being responsible for the production of the dark pigment melanin. The age-adjusted death rate has stayed relatively constant since 2010 with a slight increase in 2011 through 2013 but taking a consistent decline from 2015-2018. The death rate in the 0 to 19 years of age, is the highest for the six cancers presented in this report.



*Florida Charts

Melanoma Cancer Crude Death Rate, Single Year Rates by Age Group, Per 100,000, 2010-2018				
Years	0-19 Years of Age	20-39 Years of Age	40-64 Years of Age	65+ Years of Age
2018	0.0	0.5	2.7	10.9
2017	0.0	0.3	2.5	10.7
2016	0.0	0.2	2.6	11.8
2015	0.0	0.3	3.3	13.8
2014	0.0	0.3	3.0	14.6
2013	0.0	0.5	3.4	15.3
2012	0.0	0.6	3.5	15.3
2011	0.0	0.5	3.4	15.0
2010	0.0	0.3	3.6	12.5


Melanoma Age-Adjusted Death Rate, Single Year Rates, Per 100,000, 2010-2018	
Years	Rate
2018	2.3
2017	2.2
2016	2.3
2015	2.8
2014	2.7
2013	3.0
2012	3.1
2011	3.0
2010	2.7



*Florida Charts

Leukemia is a cancer of the blood or bone marrow characterized by an abnormal increase of blood cells, usually leukocytes (white blood cells). Leukemia is a broad term covering a spectrum of diseases. It is part of the even broader group of diseases called hematological neoplasms.


The age-adjusted death rate has reduced slightly over the 20 years and rates increase with age. Leukemia impacts the 0-19 age group slightly more than some of the cancers described in this report.



*Florida Charts


Leukemia Cancer Crude Death Rate, Single Year Rates by Age Group, Per 100,000, 2010-2018				
Years	0-19 Years of Age	20-39 Years of Age	40-64 Years of Age	65+ Years of Age
2018	0.5	1.1	4.3	35.0
2017	0.6	0.9	4.9	35.6
2016	0.5	1.1	4.8	35.7
2015	0.7	1.2	4.6	35.7
2014	0.6	1.2	5.2	37.0
2013	0.6	0.9	4.7	37.4
2012	0.5	1.0	4.4	36.5
2011	0.5	1.2	4.6	38.7
2010	0.6	1.2	4.7	35.2

Leukemia Age-Adjusted Death Rate, Single Year Rates, Per 100,000, 2010-2018	
Years	Rate
2018	6.1
2017	6.3
2016	6.3
2015	6.3
2014	6.5
2013	6.4
2012	6.2
2011	6.7
2010	6.2



*Florida Charts

Lymphoid, Hematopoietic and Related Tissue Cancers (sarcoma), stated or presumed to be primary, of lymphoid, hematopoietic and related tissue. Soft tissue sarcoma begins in various soft tissues including muscle, fat, blood vessels, nerves, tendons and linings of joints. Soft tissue sarcoma can occur anywhere but is most common in the abdomen, arms, and legs. Some risk factors found to be associated with soft tissue sarcoma are radiation, damaged lymph system, and exposure to certain chemicals. Lifestyle factors are not linked to increased risk of soft tissue sarcoma.




*Florida Charts

Lymphoid, Hematopoietic and Related Tissue Cancer death rates have steadily declined in the past 20 years in Florida. Death rates for these cancers increases with age, as with most other cancers. Some rural counties have a significantly higher death rate which could be attributed to decreased access to diagnostic care and treatment.


Lymphoid Cancer Crude Death Rate, Single Year Rates by Age Group, Per 100,000, 2010-2018				
Years	0-19 Years of Age	20-39 Years of Age	40-64 Years of Age	65+ Years of Age
2018	0.6	1.7	11.2	84.1
2017	0.7	1.4	11.9	85.5
2016	0.6	1.8	12.2	86.4
2015	0.9	1.8	12.4	87.9
2014	0.7	2.0	12.3	88.1
2013	0.7	2.0	12.5	92.1
2012	0.5	1.9	11.9	91.9
2011	0.6	2.0	12.0	92.0
2010	0.7	2.1	12.8	90.3

Lymphoid, Hematopoietic and Related Tissue Cancers Age-Adjusted Death Rate, Single Year Rates, Per 100,000, 2018-2018	
Years	Rate
2018	14.3
2017	14.6
2016	14.9
2015	15.1
2014	15.0
2013	15.7
2012	15.5
2011	15.8
2010	15.6



*Florida Charts

Brain/Central Nervous System Cancer is the growth of abnormal cells in the tissues of the brain and central nervous system. Cancerous brain and spinal cord tumors are the second most common cancers in children. Little is known about the causes of childhood and adult cancers of the brain and central nervous system. Several studies of environmental risk factors have presented inconsistent results. About 5% of brain tumors are due to hereditary factors. Risk factors are different for children than for adults. Established risk factors include exposure to therapeutic doses of ionizing radiation, rare hereditary syndromes and family history.




*Florida Charts

Cancers of the brain occur in people of all ages but more frequently in two age groups; children under the age of 15 and adults over the age of 65. Central nervous system cancers death rates have not significantly changed in the last 20 years in Florida. There is no clear geographic pattern related to central nervous system cancer death rates.

Central Nervous System Cancer Crude Death Rate, Single Year Rates by Age Group, Per 100,000, 2010-2018				
Years	0-19 Years of Age	20-39 Years of Age	40-64 Years of Age	65+ Years of Age
2018	0.6	1.0	5.8	17.1
2017	0.8	1.0	6.1	17.7
2016	0.9	0.7	5.6	16.4
2015	0.7	0.9	6.1	18.6
2014	0.7	1.0	5.9	17.1
2013	0.6	1.0	5.3	17.0
2012	0.6	1.1	6.0	17.8
2011	0.7	0.9	6.0	16.1
2010	0.6	0.9	5.3	16.5

Central Nervous System Cancer Age-Adjusted Death Rate, Single Year Rates, Per 100,000, 2010-2018	
Years	Rate
2018	4.2
2017	4.4
2016	4.1
2015	4.5
2014	4.3
2013	4.1
2012	4.4
2011	4.2
2010	4.0



*Florida Charts

Federal Funding Awarded to Florida Institutions for Cancer-Related Research

Cancer research efforts in Florida are amplified through federal funds. The William G. “Bill” Bankhead, Jr., and David Coley Cancer Research Program Funding (Bankhead-Coley) seeks to provide research grant funding to proposals that demonstrate the greatest opportunity to attract federal research grants and private financial support. It is recognized that state research grant funding can result in federal funding awards for Florida. Annually, the Bankhead-Coley Funding Opportunity Announcement includes bridge grants as a mechanism of support to provide interim support for promising investigator-initiated research projects that have been highly rated by national panels of peer reviewers in recent federal competitions but were not funded due to budgetary constraints. To be eligible, applicants must have submitted a multi-year, investigator-initiated research application to a federal agency (such as an NIH Research Grant type). The applicant must have received a peer-review summary statement indicating high scientific merit. For purposes of this competition, “high scientific merit” is a percentile ranking of 16th or better.

Florida cancer researchers are successful in receiving federal research grants. Florida has ranked 12th since 2015. The following charts indicate the federal funding awarded to Florida, by funding institution, for fiscal years 2016-2018.

Federal Research Funding 2018

State	NIH Funding	Rank	Total (NIH, CDC, NSF, AHRQ)	Rank
Maryland	\$6,082,592,894	1	\$6,204,054,404	1
California	\$4,268,156,656	2	\$4,925,661,349	2
New York	\$2,721,214,815	3	\$3,046,062,774	3
Massachusetts	\$2,580,853,712	4	\$2,919,465,079	5
Texas	\$2,411,238,165	5	\$2,961,135,872	4
Pennsylvania	\$1,819,514,098	6	\$2,030,364,116	6
North Carolina	\$1,414,972,178	7	\$1,588,442,358	7
Washington	\$1,050,341,726	8	\$1,166,339,951	8
Illinois	\$897,317,224	9	\$1,123,464,829	9
Ohio	\$826,541,432	10	\$988,622,243	10
Michigan	\$766,843,447	11	\$924,038,587	11
Florida	\$618,845,829	12	\$790,045,553	12
Missouri	\$608,474,422	13	\$660,258,064	14
Georgia	\$584,693,360	14	\$689,764,758	13
Connecticut	\$562,457,473	15	\$621,884,759	15
Tennessee	\$553,004,151	16	\$610,435,989	16

*<http://federalreporter.nih.gov>

Federal Research Funding 2017

State	NIH Funding	Rank	Total (NIH, CDC, NSF, AHRQ)	Rank
Maryland	\$5,934,859,563	1	\$6,023,913,839	1
California	\$3,967,869,664	2	\$4,492,149,403	2
Massachusetts	\$2,713,448,621	3	\$3,050,469,757	3
New York	\$2,395,714,297	4	\$2,729,618,358	4
Pennsylvania	\$1,683,152,973	5	\$1,894,325,648	5
North Carolina	\$1,263,225,962	6	\$1,418,878,289	7
Texas	\$1,164,300,861	7	\$1,419,121,134	6
Washington	\$996,513,493	8	\$1,110,140,206	8
Illinois	\$804,576,026	9	\$1,002,177,060	9
Ohio	\$753,040,994	10	\$847,897,065	11
Michigan	\$712,608,048	11	\$886,638,921	10
Florida	\$655,243,968	12	\$781,207,921	12
Missouri	\$536,017,488	13	\$583,262,817	15
Georgia	\$535,209,334	14	\$632,251,330	13
Connecticut	\$530,135,134	15	\$593,833,813	14
Tennessee	\$514,116,999	16	\$553,322,442	16

*<http://federalreporter.nih.gov>

Federal Research Funding 2016

State	NIH Funding	Rank	Total (NIH, CDC, NSF, AHRQ)	Rank
Maryland	\$8,276,520,416	1	\$8,735,452,727	1
New York	\$4,599,766,123	2	\$5,271,723,095	2
California	\$3,722,223,847	3	\$4,299,435,103	3
Pennsylvania	\$3,251,039,876	4	\$3,679,334,607	4
Massachusetts	\$2,580,853,712	5	\$2,919,465,079	5
North Carolina	\$2,450,604,789	6	\$2,755,683,269	6
Texas	\$1,094,529,926	7	\$1,338,494,808	7
Washington	\$962,123,566	8	\$1,078,590,567	8
Illinois	\$821,344,507	9	\$1,041,444,224	9
Ohio	\$736,903,837	10	\$951,448,278	10

National Cancer Institutes in Florida Report 2020

Michigan	\$673,889,585	11	\$822,332,856	11
Florida	\$546,342,368	12	\$669,086,254	12
Georgia	\$522,474,125	13	\$632,692,719	13
Connecticut	\$512,698,188	14	\$577,483,175	14
Tennessee	\$512,308,194	15	\$577,093,416	15
Missouri	\$506,301,917	16	\$573,176,455	16

*<http://federalreporter.nih.gov>

The Florida National Cancer Institutes

The Department established agreements with the three Florida-based National Cancer Institutes: H. Lee Moffitt Cancer Center, University of Florida Shands Cancer Hospital and University of Miami Sylvester Comprehensive Cancer Center. The goal of the agreements is to enhance the quality and competitiveness of cancer care in this state, further a statewide biomedical research strategy directly responsive to the health needs of Florida's citizens, and capitalize on the potential educational opportunities available to its students by providing support to obtain and maintain recognition as a NCI Designated Comprehensive Cancer Center.

Annually the institutes provide a report on the following:

- a. Cancer-related basic scientific research conducted and cancer-related population scientific research.
- b. Services provided on site that offer the full range of cancer diagnostic and treatment services, as determined by the Commission on Cancer of the American College of Surgeons.
- c. Interventional clinical trials that are hosted by the NCI or conducted cancer-related interventional clinical trials that are registered with the NCI's Clinical Trials Reporting Program.
- d. Offer degree-granting programs or affiliate with universities through degree-granting programs accredited or approved by a nationally recognized educational accrediting body and offered through provider or through provider in conjunction with another institution accredited by the Commission on Colleges of the Southern Association of Colleges and Schools. Prepare a report documenting completion of this task.
- e. Provide training to clinical trainees, medical trainees accredited by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association and postdoctoral fellows recently awarded a doctorate degree.
- f. Annually maintain in excess of \$5 million in direct costs associated with Provider's NCI peer-reviewed grant funding. Prepare a report documenting completion of this task.
- g. Prepare an annual report which includes peer review costs, reportable cases, reportable cases of patients enrolled in institutional or investigator-initiated interventional clinical trials, biomedical education and training and submit it to the Department by July 15th of each year of the agreement.
- h. Prepare and submit a NCI P30 Cancer Center Support Grant application, application for renewal or documentation of award by July 2019.
- i. Maintain a report listing the full range of diagnostic and treatment services provided by the cancer center, updated on an annual basis.

As required in this report the following will now be addressed: collaborative efforts focusing on grants and interinstitutional agreements among participating cancer centers, a comparison of

National Cancer Institutes in Florida Report 2020

collaborative grants in proportion to the grant totals for each cancer center, a catalogue of retreats and progress seed grants using state funds and targets for collaboration in the future and reports on progress regarding such targets where appropriate. Information will be provided on each of the three NCI's for Fiscal Year (FY) 16-17, 17-18 and 18-19. FY 19-20 report is due to the Department by July 15th and is not included here. Please see the attached document submitted by the Florida Consortium of NCI Centers Program.

Overview

The Florida Academic Cancer Center Alliance (FACCA), consisting of the Moffitt Cancer Center (Moffitt), the University of Florida Health Cancer Center (UF Health), and the Sylvester Comprehensive Cancer Center (Sylvester) at the University of Miami, formed in 2014 to build collaborations between the centers to expedite innovation in the area of cancer research throughout the State of Florida and maximize state investments in biomedical technology and research.

A primary goal of the program at the time of creation was to provide support for UF Health and Sylvester to obtain NCI designation and for Moffitt to sustain NCI Comprehensive designation. Since the last report, we are proud to report that Sylvester obtained NCI designation in July 2019, becoming the 71st designated Cancer Center and the 2nd in the State of Florida. NCI recognized Sylvester for its outstanding work conducting research in its laboratories, treating patients in its clinics and hospitals and reaching out to medically underserved communities with innovative prevention strategies. Moffitt continues as an NCI-designated Comprehensive Cancer Center and will undergo competitive renewal again in 2021. UF Health submitted its first competitive Cancer Center Support Grant (CCSG) application to NCI in 2019 and was recommended for designation by the review committees; however, NCI declined approval for designation. UF Health is planning a resubmission in 2022.

Over the past three years, the extraordinary partnership has strengthened its efforts to advance cancer care, research and education throughout the state of Florida. The foundation of this relationship is engaged collaboration among faculty and staff at the centers. Examples of progress over the last three years include:

Recognition of Sylvester as an NCI designated Cancer Center

Treatment of 67,174 newly diagnosed patients (reportable cases combined for FY17-FY19) and since the program's inception 102,696 patients (FY15-FY19).

Through collaborative pilot grant mechanism awarded 19 collaborative interinstitutional projects since 2015

Funding for two targeted "think tanks" in the areas of the microbiome and health disparities. Two additional think tanks in the areas of Immunotherapy and epigenetics are in the planning stage.

29,588 training experiences for current and future clinicians and scientists over the last three years and 45,706 since the program's inception.

Over 75 distinct collaborative publications featuring members of at least two FACCA institutions in the past three years (13 between Sylvester/UF Health; 53 between Moffitt/UF Health; and 9 between Moffitt/Sylvester/UF Health).

Building upon the success of the 2015 joint retreat, three FACCA-wide retreats (2017 at Lake Nona, hosted by UF Health, 2018 in Tampa hosted by Moffitt and 2019 in Miami hosted by Sylvester).

Regular communication and collaboration among the Directors.

Semi-annual in-person Directors and Administrators retreats, semi-annual teleconference retreats.

Monthly Administrators conference calls.

Research collaborations through conferences and workshops (see FACCA Collaborations below).

Moffitt

Overview

Moffitt's designation by NCI as a Comprehensive Cancer center was officially renewed on February 1, 2017 with the start of year 19 of funding for the Cancer Center Support Grant (CCSG). With recent support from its External Advisory Committee, Moffitt is currently working on its next competitive renewal and will be submitting its application in January 2021. The approved, the new grant cycle will go into effect February 2022 and reaffirm Moffitt's designation as a Comprehensive Cancer Center for another five years.

Several leadership roles were filled over the last two years marking the beginning of an exciting new period in Moffitt's growth and evolution as a Cancer Center as it proactively addresses the needs of Floridians, the rising expectations of the CCSG and scientific trends in cancer research. John Cleveland, PhD, was named Executive Vice President/Center Director and in that role has direct authority over all research activities at Moffitt, which includes oversight of the CCSG. Other notable appointments since 2017 include Shelley Tworoger, PhD as Associate Center Director of Population Science, Dana Rollison, PhD as Associate Center Director of Data Science, Susan Vadaparampil, PhD as Associate Center Director of Community Outreach, Engagement, and Equity, Eric Haura, MD, as Associate Center Director of Clinical Science and Kenneth Wright, PhD, Director of Research Education and Training.

Faculty and Staff Recruitment

The state's investment has enabled Moffitt to recruit 52 research faculty at all ranks over the last three years (primarily from out of state), competing successfully for top-tier scientists against larger, more established institutions including:

Dennis Adeegbe, MD, from the New York University Langone Medical Center

Anna Coghill, PhD, MPH, from the NCI

Assam El Naqa PhD, from the University of Michigan,

Elsa Flores, PhD, from MD Anderson

Ross Mitchell, PhD, from the Mayo Clinic, Scottsdale, Arizona

Shelley Tworoger, PhD, from Harvard,

Michael Vogelbaum, MD from the Cleveland Clinic

Investment in new faculty includes attractive start-up funding for them to jump start and supplement their research as a necessary and foundational step towards competing for extramural funding, especially from the NCI. These funds allow faculty to develop preliminary data and generate ideas necessary to obtain grant funding, to develop clinical trials and to apply new knowledge to provide outstanding patient care. As recent example, Moffitt was able to recruit during the COVID-19 pandemic, a new Chair of Machine Learning to oversee Moffitt's growing research activities in artificial intelligence who will begin in August 2020. Notable hires across the five research programs to leadership positions during the last three years (FY18-20) include:

Elsa Flores, PhD, Chair, Molecular Oncology

Brooke Fridley, PhD, Chair, Biostatistics & Bioinformatics

Derek Duckett, PhD, Chair, Drug Discovery

Aik Choon Tan, PhD, Vice Chair of Biostatistics & Bioinformatics

Shelley Tworoger, PhD, Associate Center Director, Population Science

Jennifer Vidrine, PhD, Assistant Center Director, Research Partnerships

Michael Vogelbaum, MD, Program Leader, Neuro-Oncology

Of note, 12 junior faculty recruited since 2016 have obtained their first R01 or equivalent, which is a remarkable achievement for their career development and a reflection of the quality mentoring and supportive research environment available at Moffitt.

UF Health

Overview

Through the funding provided from the State of Florida over the past three years, UF Health has made significant strides toward its goal of achieving NCI designation. Tangible results have been achieved to include the submission of the first-ever CCSG application from UF Health to NCI for designation in 2019; national recognition by the National Pancreas Foundation by naming UF Health as one of only 28 health care facilities in the nation as a Center of Excellence; nationally ranked by US News & World Report for both adult and pediatric cancer hospitals, and ranked among the nation's best in six specialties. The funding provided to UF Health has enabled the Center to improve treatment options for patients and achieve research excellence providing patients access to higher levels of interdisciplinary discoveries to improve cancer treatments at the state's most comprehensive academic medical center. UF is internationally recognized for its research expertise and clinical care in bone marrow transplant, brain tumors, leukemia and lymphoma, pancreatic, prostate, and sarcoma cancers. UF Health continues pioneering work in areas such as microbiota research applications and immunotherapy treatment for cancers, bringing together researchers from 39 Departments in 11 of the 16 UF Colleges.

Faculty and Staff Recruitment

Continued faculty recruitment is an ongoing initiative and recognized as essential for UF Health's resubmission application to NCI, planned for 2022. During the period of 2017–2019, state funding has been a critical resource in the successful recruitment of a total of 20 strategic faculty recruits from 14 other states, including four established NCI-Designated Cancer Centers, to the cancer center that involved the collaboration and coordination between the cancer center and 13 departments in five colleges. Among the recent recruits include:

David DeRemer, PharmD, Assistant Director, Experimental Therapeutics Clinical Trials Incubator

Biljana Horn, MD, Director, Pediatric Bone Marrow Transplant and Cell Therapy Program

Ji-Hyun Lee, PhD, Director, Division of Quantitative Sciences, Director, Biostatistics Shared Resource

Daohong Zhou, MD, Research Program Leader, Mechanism of Oncogenesis

Of the 20 recruits to UF Health in the past three years, eight (40%) have been successful in obtaining peer-reviewed funding, since arriving to UF. This includes seven (47%) awards from NCI, four awards from NIH, and four awards from other peer-review organizations that total \$16,346,281 (total costs, all years) to UF. Through 2019, the recruits have expensed \$4,296,049 from UF Health recruitment support, generating a ROI of ~4:1.

Sylvester

Overview

The Sylvester Comprehensive Cancer Center (Sylvester) at the University of Miami is the only academic Cancer Center in South Florida and became the 71st NCI designated Cancer Center in July 2019. Sylvester's catchment area, a four-county region (Broward, Miami-Dade, Monroe, and Palm Beach Counties) known as South Florida, is home to more than six million people of diverse ancestry, racial/ethnic identities, socioeconomic and cultural backgrounds. This diversity is reflected in the patients Sylvester treats and the disparate communities the Center reaches through its community outreach and engagement efforts. The racial and ethnic heterogeneity of the catchment area presents Sylvester's investigators with unique and important

opportunities to advance cancer research. Implicit in Sylvester's mission is a deep commitment to achieve health equity in the context of the disparities prevalent in its catchment area. Over the past six years, led by its Director, Stephen D. Nimer, MD, Sylvester has built an impressive core of cancer researchers and health professionals to best position itself as a national leader in cancer research, with teams of outstanding scientists who conduct impactful, collaborative and transdisciplinary research. Represented among Sylvester's 114 cancer researchers, twenty-two academic disciplines are largely distributed throughout its three Research Programs—Cancer Control (CC), Cancer Epigenetics (CE) and Tumor Biology (TB). Their diverse interests, perspectives and expertise advance the Center's competency in identifying opportunities and responding to unique challenges within South Florida.

With the support from the State of Florida appropriation, Sylvester has invested heavily in its basic, clinical, translational, and population-based research and research infrastructure, bringing new scientists and expert leadership to develop its Research Programs, shared resources and clinical research services. Investments in the clinical research infrastructure have led to dramatic increases in Investigator-Initiated Trials (IIT) interventional accruals to now over 1507 in 2019, with more than 50% of the 4,568 total accruals representing racial/ethnic minorities. Investments in education and training have also yielded important funding milestones: five recently awarded NIH or NCI-funded T32 training grants, a U54 grant with Argentina and a Paul Calabresi K12 grant totaling over \$2.2M (annual direct costs). Finally, Sylvester has invested in Pilot Funding and Think Tank Program with Moffitt and UF yielding publications and peer-reviewed funding as outlined below. Overall cancer-related funding for Sylvester has increased from \$25.4M in 2017 to \$32.9M in 2019 with \$10.4M from NCI.

Faculty and Staff Recruitment

Due to the support of the State of Florida Appropriation and the rising reputation of the quality of clinical care and research at Sylvester, the Cancer Center has been able to recruit physicians and investigators from institutions with good reputations to Florida. Since 2012, 41 recruits have been brought to the Center. Below is a partial list of the recruits joining Sylvester during the reporting period, each bringing expertise, grant funding and/or clinical trials to the State of Florida.

Welford, Scott, PhD, Case Western Reserve University

Perez, Cesar, MD, University of Louisville

Dal Pra, Alan, MD, Inselspital, Bern

Tang, Jennifer, MD, Laser and Skin Center of Indiana

EI-Rifai, Wael, MD, PhD, Vanderbilt University

Zaika, Alex, PhD, Vanderbilt University

Pinheiro, Paulo, PhD, University of Nevada

Moskowitz, Craig, MD, Memorial Sloan Kettering Cancer Center

Cimmino, Luisa, PhD, New York University

D'Amato, Gina, MD, Georgia Cancer Specialists

Goel, Goel, MD, Fox Chase Cancer Center

Penedo, Frank, PhD, Northwestern University

Rieger, Sandra, PhD, Mount Desert Island Biological Lab

Zhou, Yi MD, PhD, University of Washington

Dhabhar, Firdaus, PhD, Stanford University

Ramakrishnan, Sundaram, PhD, University of Minnesota

Roy, Sabita, PhD, University of Minnesota

Figueroa, Maria, MD, University of Michigan


Bedogni, Barbara, PhD, Case Western Reserve University

Datta, Josh, MD, Memorial Sloan Kettering

By providing start-up packages to recruit 41 top cancer scientists (nine for Cancer Control, nine for Cancer Epigenetics, 16 for Tumor Biology and seven non-programmatically aligned members), Sylvester has greatly strengthened the University's cancer focus and improved the overall research climate and environment, enabling all Sylvester members to conduct more collaborative, multidisciplinary, high-impact research and be more successful at garnering highly competitive, peer-reviewed grant funding resulting in peer-reviewed cancer funding growing significantly.

Funding Trends


The centers have all separately and together increased the amount of grant funding for cancer research brought to the State of Florida. Cancer related peer-reviewed funding, primarily from NCI and other NIH sponsors, grew over the last three years by over 12% from \$96.3 million to \$108.2 million.



Peer reviewed funding defined as annual direct costs of cancer related awards to each institution based on sponsors considered by NCI Cancer Centers branch as peer-reviewed

To provide context, within the state, the three centers together make up 71% of state funding from NCI, demonstrating the leadership throughout the state, as shown below.

Figure 2. FY2019 Florida NCI Funding



Data based on NIH RePORTER data filtered by the most current completed NIH fiscal year (2019) and limited to NCI funding to demonstrate cancer focus across all organizations.

Based on NIH RePORT data, Florida is currently the 14th highest funded state based on NCI grants. As the nation's 3rd most populous state, there is room for improving the grant dollars awarded to the state. The three FACCA institutions are best equipped to increase the amount of cancer related grant funding to the state with the Centers Program providing critical support.

Moffitt

In 2019 the overall peer-reviewed funding, based on NIH RePORT data, for Moffitt was \$40.9M (**Fig. 1**), representing 265 research projects being conducted by its membership. Overall, NCI funding to Moffitt has increased over 10% from \$28.7M in 2017 to \$31.6M annually in 2019 (**Fig. 2**).

Moffitt faculty published 995 articles in calendar year 2019, including many top-tier journals. Among research programs, there were 868 total publications. Intra-program collaboration rates were 24.5% overall and 18.8% for inter-programmatic collaborations. Overall average impact factor for this period was 7.164 and included many publications in top-tier journals including *New England Journal of Medicine*, *Nature*, and *Science*.


The demand for care at Moffitt reflects the numerous opportunities to participate in clinical trials and the resulting superior outcomes. Therapeutic clinical trial accrual grew to 1,218 in FY 2019 and is poised to exceed that number in 2020, even with the temporary impact of COVID-19. Moffitt Cancer Center primarily serves Floridians, with 96.7% of its patients coming from Florida, but also serves as a magnet for many out-of-state and international cancer patients. In FY2019, Moffitt continued to grow with 9,465 admissions, 23,760 new patients and 450,116 outpatient visits.

UF Health

In 2019 the overall peer-reviewed funding for UF Health was \$34.3M (Fig. 1), representing 166 research projects being conducted by its membership. Overall, NCI funding to UF Health has increased over 24% from 2017 to \$12.8M annually in 2019 (Fig. 2). Total NCI funding represents 39% of the total peer-reviewed research being conducted at UF Health.

UF Health members had a total of 1,242 peer-reviewed publications during 2017-2019. Of the total publications, 24% were intra-programmatic, 13% were inter-programmatic and 63% of all publications were inter-institutional that included 75 collaborative publications with researchers at Moffitt and Sylvester

Between 2017 and 2019 UF Health saw 24,301 new patients, of which 3,302 (>13%) enrolled onto IIT clinical trials. In 2019, there were 39 open UF Health Cancer Center IITs and 209 actively accruing interventional protocols of all types, particularly treatment, screening and supportive care.



Sylvester

Since 2017, Sylvester's NCI-funding base has also grown from \$6.9M to \$10.4M in 2019 in annual direct costs while the total peer-reviewed funding has increased from \$25.4M to \$32.9.4M. In FY 2019 alone, Sylvester investigators were awarded 51 new cancer-related grants and contracts. Of these grants, 15 were received by faculty holding Sylvester Endowed positions.

Sylvester investigators have published a total of 847 peer-reviewed cancer relevant journal articles for calendar years 2017, 2018 and 2019. One hundred and forty of the publications are published in journals with an impact factor greater than 10 and represent a high degree of collaboration among Sylvester's investigators. The percentage of publications between Sylvester research programs (inter-programmatic publications) is 9% while collaboration within research programs (inter-programmatic publications) is 25%. Twenty-eight percent of publications by Sylvester investigators are in collaboration with other NCI-designated cancer centers.

New cancer patients receiving treatment at Sylvester (analytic cases) has increased from 4,536 in 2017 to 5,805 in 2019. The patients accrued to interventional treatment trials represent 11% of our newly diagnosed patients and reflects the racial and ethnic diversity of our catchment area.

Collaborations among the Florida-based NCIs

Grants

Moffitt

Moffitt researchers collaborated on nine funded research projects with members of UF Health and Sylvester through the FACCA pilot funding mechanism from 2017-2019. To date, these collaborations plus the seven collaborative grants from 2015 and 2016 have resulted in 10 publications and four grants (an NCI R37, two Florida Biomedical Bankhead Coley awards and a VA award) directly related to these projects. Once projects are completed, they can take years to develop into new grants and publication. Thus, the impact of the pilot funding is ongoing and are likely to have their greatest resulting impact in the next period. The table below summarizes the collaborative FACCA pilots involving Moffitt and outcomes to date:

Table 1. Moffitt Collaborative FACCA Pilot Projects

Award Number	Investigators	Project Title
FACCA-2019-02	Davila, Marco (Moffitt) Schatz, Jonathan (Sylvester)	Determinants of response to CAR-T cellular immunotherapy in aggressive B-cell lymphomas
FACCA-2019-03	Smalley, Keiran (Moffitt) Wang, Gaofeng (Sylvester)	Epigenetically reversing BRAF inhibitor resistance in melanoma by vitamin C
FACCA-2018-02	Wilkie, Diana (UF Health) Kobetz, Erin (Sylvester) Vadaparampil, Susan (Moffitt)	FACCA - Disparities Think Tank
FACCA-2018-01	Jobin, Christian (UF Health) Pierce, Christine (Moffitt) Abreu, Maria (Sylvester)	Role of intestinal microbiota in lung cancer therapy
FACCA-2017-15	Trevino, Jose (UF Health) Permuth, Jenny (Moffitt) Malafa, Mokenge (Moffitt) Merchant, Nipun (Sylvester)	The Florida pancreas collaborative: A partnership dedicated to the prevention and early detection of pancreatic cancer
<p>Outcomes:</p> <ol style="list-style-type: none"> Permuth JB, Trevino J, Merchant N and Malafa M. Partnering to advance early detection and prevention efforts for pancreatic cancer: the Florida Pancreas Collaborative. <i>Future Oncol.</i> 2016. Permuth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M, On Behalf Of The Florida Pancreas Collaborative. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. <i>Oncotarget.</i> 2016 Dec 27;7(52):85785-85797 doi: 10.18632/oncotarget.11768. PMID: 27589689 Permuth JB, Choi JW, Chen D, Jiang K, DeNicola G, Li J, Coppola D, Centeno BA, Magliocco A, Balagurunathan Y, Merchant N, Trevino JG, Jeong D. A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? <i>Can Bio & Med.</i> 2017 Feb 15;14(1):66-73) Permuth JB, Chen D, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth F, Trevino JG, Merchant N, Magliocco, Malafa MP, Gillies R. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Sci Rep.</i> 2017 Sep 5;7(1):10484. doi: 10.1038/s41598-017-09754-5. PMID: 28874676 Permuth J, Clark Daly A, Jeong D, Choi J, Cameron M, Chen D, Teer J, Barnett T, Li J, Powers B, Kumar N, George T, Ali K, Huynh T, Vyas S, Gwede C, Simmons V, Hodul P, Carballido E, Judge A, Fleming J, Merchant N, Trevino J. (2019) Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. <i>Cancer Med</i> 8(6):3314-3324. PMID: 31074202 PMC ID: PMC6558500 <p>NCI R01 CA229810 (MPIs Jennifer Permuth & Daniel Jeong) "Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology"; 7/1/19-6/30/24; \$4,148,118 total project costs</p>		
FACCA-2017-10	Shenkman, Elizabeth (UF Health) Giuliano, Anna (Moffitt) Jones, Patricia (Sylvester)	Florida Increases Rates of Screening and Treatment of Hepatitis C Virus (FIRST HCV)
<p>Outcomes:</p> <p>Kasting M, Giuliano A, Reich R, Roetzheim R, Duong L, Thomas E, Nelson D, Shenkman E, Vadaparampil S. (2019) Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. <i>Cancer Epidemiol</i> (60):112-120. PMID: 30953971 PMC ID: PMC6527446</p> <p>Kasting M, Giuliano A, Reich R, Roetzheim R, Nelson D, Shenkman E, Vadaparampil S. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. <i>Cancer Epidemiol. Biomarkers Prev.</i> 27(4):503-513. PMID: 29588306 PMC ID: PMC5884715</p>		
FACCA-2017-16	Markham, Merry Jennifer (UF Health) Hicks, Amanda (UF Health) Quinn, Gwendolyn (Moffitt) Schabath, Matthew (Moffitt) Schlumbrecht, Matthew (Sylvester) Seay, Julie (Sylvester)	Developing Provider-Focused LGBT Communication Skill Building for Oncologists

Outcomes:		
1. Seay J, Hicks A, Markham MJ, Schlumbrecht M, Bowman-Curci M, Woodard J, Duarte LF, Quinn GP, Schabath MB. Web-based LGBT cultural competency training intervention for oncologists: Pilot study results. <i>Cancer</i> . 2019 Sep 16. doi: 10.1002/cncr.32491. PMID: 31524952		
2. Seay J, Hicks A, Markham MJ, Schlumbrecht M, Bowman M, Woodard J, Kollfrath A, Diego D, Quinn GP, Schabath MB. Developing a web-based LGBT cultural competency training for oncologists: The COLORS training. <i>Patient Educ Couns</i> . 2019 Jan 7. pii: S0738-3991(18)30531-7. doi: 10.1016/j.pec.2019.01.006. PMID: 30642714		
FACCA-2017-01	Forsyth, Peter (Moffitt) Noriyuki, Kasahara (Sylvester)	Virotherapy combination strategy for glioblastoma

Collaborations between Moffitt and the FACCA members extends beyond the pilot projects, reflecting the collaborative culture at all three institutions. For example, during the last three years, Moffitt's Dr. Tom Brandon collaborated with the University of Miami on a Bankhead Coley funded project addressing racial and ethnic tobacco health disparities. Dr. Gillies collaborated with Sylvester to investigate MRI imaging and genetic signatures to manage prostate cancer overdiagnosis, and Dr. Lynch collaborated with Sylvester to study redox stress-mediated inappropriate androgen receptor elevation as a novel treatment paradigm for castration-resistant prostate cancer. With UF Health, Dr. Egan collaborated on a study of urinary estrogen and gut microbiome composition in healthy postmenopausal women. As noted above, Dr. Permuth is collaborating with both Sylvester and UF Health on the Bankhead Coley funded Florida pancreas collaborative next-generation biobank-reducing health disparities and improving survival in pancreatic cancer. A summary of grants based at Moffitt over the last three years that involve collaborations with UF Health or Sylvester as demonstrated through a subcontract

Table 2. Moffitt Active Collaborations on Externally Funded Research Projects

Title	Moffitt PI	Prime Sponsor	Prime Sponsor #	Year Start Date	Year End Date	Subrecipient	PI
(PQC4) Habitats in Prostate Cancer	Gillies, Robert	NIH/NCI	CA190105	9/1/2016	8/31/2019	Sylvester	Alan Pollack
Causes and Consequences of Acid pH in Tumors - Supplement	Gillies, Robert	NIH/NCI	CA077575	8/1/2016	7/31/2018	UF Health	Timothy Garrett
Biobank for African American Prostate Cancer Research in Florida	Park, Jong	Florida Biomedical	6JK06	3/21/2016	8/31/2019	UF Health	Shahia Masood
Tumor Infiltrating Lymphocyte Adoptive T Cell Therapy for NSCLC	Antonia, Scott	Stand Up To Cancer	SU2C-AACR-CT04-17	6/1/2017	5/31/2020	UF Health	Frederic Kaye
Sequence Variation in mtDNA and Extreme Survival in Glioblastoma	Egan, Kathleen	NIH/NCI	CA216227	5/11/2017	4/30/2021	Sylvester	Sion L. Williams
Defining and Targeting Epigenetic Deregulation in Uveal Melanoma	Smalley, Keiran	Florida Biomedical	7BC05	4/12/2017	6/30/2020	UF Health	Jonathan Licht
Targeting the Lipogenic Phenotype Induced by Extracellular Acidosis in Breast Cancer	Gillies, Robert	Florida Biomedical	8BC04	3/21/2018	3/31/2020	UF Health	Timothy Garrett
Early Life Exposures and Risk of Developing Ovarian Cancer	TwoRoger, Shelley	Florida Biomedical	9JK02	8/15/2019	6/30/2020	UF Health	Danielle Jake-Schoffman

UF Health

UF Health researchers collaborated on 8 funded research projects with members of Moffitt and Sylvester through the FACCA pilot funding mechanism from 2017-2019. Two peer-reviewed awards were obtained in the same period based on previously reported FACCA pilots. These awards were BCRP 7BC05 (Licht, UF Health PI) and

KEKRP 8JK02 (Trevino, UF Health PI). The current period FACCA pilot awards have generated 3 peer-reviewed publications to date. The period of time being reported on (2017-2019) does not provide sufficient time to measure the impact of the funding on peer-reviewed awards. The table below provides the collaborative nature of the FACCA pilots and outcomes to date that involve UF Health researchers, to date:

Table 3. UF Health Collaborative FACCA Pilot Projects

Award Number	Investigators	Project Title
FACCA-2019-01	Lele, Tanmay (UF Health) Xu, Michael (Sylvester)	Nuclear envelope defect and generation of micronuclei in ovarian cancer development and immune therapy
FACCA-2019-04	Kladde, Michael (UF Health) Ayad, Nagi (Sylvester)	Epigenetic basis of glioblastoma chemoresistance
FACCA-2018-02	Wilkie, Diana (UF Health) Kobetz, Erin (Sylvester) Vadamampil, Susan (Moffitt)	FACCA - Disparities Think Tank
FACCA-2018-01	Jobin, Christian (UF Health) Pierce, Christine (Moffitt) Abreu, Maria (Sylvester)	Role of intestinal microbiota in lung cancer therapy
FACCA-2017-15	Trevino, Jose (UF Health) Permeth, Jenny (Moffitt) Malafa, Mokenge (Moffitt) Merchant, Nipun (Sylvester)	The Florida pancreas collaborative: A partnership dedicated to the prevention and early detection of pancreatic cancer
Outcomes:		
<ol style="list-style-type: none"> Permeth JB, Trevino J, Merchant N and Malafa M. Partnering to advance early detection and prevention efforts for pancreatic cancer: the Florida Pancreas Collaborative. <i>Future Oncol.</i> 2016. Permeth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M, On Behalf Of The Florida Pancreas Collaborative. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. <i>Oncotarget.</i> 2016 Dec 27;7(52):85785-85797 doi: 10.18632/oncotarget.11768. PMID: 27589689 Permeth JB, Choi JW, Chen D, Jiang K, DeNicola G, Li J, Coppola D, Centeno BA, Magliocco A, Balagurunathan Y, Merchant N, Trevino JG, Jeong D. A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? <i>Can Bio & Med.</i> 2017 Feb 15;14(1):66-73) Permeth JB, Chen D, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth F, Trevino JG, Merchant N, Magliocco, Malafa MP, Gillies R. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Sci Rep.</i> 2017 Sep 5;7(1):10484. doi: 10.1038/s41598-017-09754-5. PMID: 28874676 Permeth J, Clark Daly A, Jeong D, Choi J, Cameron M, Chen D, Teer J, Barnett T, Li J, Powers B, Kumar N, George T, Ali K, Huynh T, Vyas S, Gwede C, Simmons V, Hodul P, Carballido E, Judge A, Fleming J, Merchant N, Trevino J. (2019) Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. <i>Cancer Med</i> 8(6):3314-3324. PMID: 31074202 PMC ID: PMC6558500 		
FACCA-2017-10	Shenkman, Elizabeth (UF Health) Giuliano, Anna (Moffitt) Jones, Patricia (Sylvester)	Florida Increases Rates of Screening and Treatment of Hepatitis C Virus (FIRST HCV)
Outcomes:		
<p>Kasting M, Giuliano A, Reich R, Roetzheim R, Duong L, Thomas E, Nelson D, Shenkman E, Vadaparampil S. (2019) Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. <i>Cancer Epidemiol</i> (60):112-120. PMID: 30953971 PMC ID: PMC6527446</p> <p>Kasting M, Giuliano A, Reich R, Roetzheim R, Nelson D, Shenkman E, Vadaparampil S. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. <i>Cancer Epidemiol. Biomarkers Prev.</i> 27(4):503-513. PMID: 29588306 PMC ID: PMC5884715</p>		

FACCA-2017-16	Markham, Merry Jennifer (UF Health) Hicks, Amanda (UF Health) Quinn, Gwendolyn (Moffitt) Schabath, Matthew (Moffitt) Schlumbrecht, Matthew (Sylvester) Seay, Julie (Sylvester)	Developing Provider-Focused LGBT Communication Skill Building for Oncologists
Outcomes:		
<ol style="list-style-type: none"> 1. Seay J, Hicks A, Markham MJ, Schlumbrecht M, Bowman-Curci M, Woodard J, Duarte LF, Quinn GP, Schabath MB. Web-based LGBT cultural competency training intervention for oncologists: Pilot study results. Cancer. 2019 Sep 16. doi: 10.1002/cncr.32491. PMID: 31524952 2. Seay J, Hicks A, Markham MJ, Schlumbrecht M, Bowman M, Woodard J, Kollefrath A, Diego D, Quinn GP, Schabath MB. Developing a web-based LGBT cultural competency training for oncologists: The COLORS training. Patient Educ Couns. 2019 Jan 7. pii: S0738-3991(18)30531-7. doi: 10.1016/j.pec.2019.01.006. PMID: 30642714 		
FACCA-2017-17	Sayour, Elias (UF Health) Gilboa, Eli (Sylvester)	Preventative vaccination against neoantigens in MRD and premalignant settings

In addition, since 2017 UF Health members collaborated with researchers from 5 Moffitt and 4 Sylvester researchers on 8 funded peer-reviewed awards that produced \$15,835,954 in total funding (total costs, all years). As stated above, 2 awards emanated from FACCA pilot awards. Specifically, KEKRP 8JK02 (Trevino, UF Health PI) is based on the work conducted originally on FACCA-2015-24, and BCRP 7BC05 (Licht, UF Health PI) resulted from the work conducted on FACCA-2016-18. Funding from the peer-reviewed awards was \$576,526 (total costs, all years), UF Health provided a total of \$100,000 to support the FACCA pilots, generating a ROI of ~6:1. The table below provides details on the collaborative funded projects.

Table 4. UF Health Active Collaborations on Peer-Reviewed Research Projects

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Collab Instit	Collab	UF Total Funding
Peer Reviewed Research Grants								
Frost S	NCI	R01 CA165284	4/1/13	3/31/19	Carbonic Anhydrase and PH Control in Breast Cancer	Moffitt	David Morse	622,500
Kaye F	AACR - SU2C	74-19122-01-01-G1	8/15/18	5/31/19	SU2C - Tumor Infiltrating Lymphocyte Adoptive T-cell Therapy for NSCLC	Moffitt	Scott Antonia	19,486
Licht J L	FLDOH Biomed Res Program	BCCRP 7BC05	4/12/17	2/29/20	Defining and Targeting Epigenetic Deregulation in Uveal Melanoma	Moffitt Sylvester	Keiran Smalley William Harbour	457,400
Licht J L	FLDOH Biomed Res Program	BCCRP 8BC03	2/18/18	5/31/21	Defining and Therapeutically Targeting HDAC8-Driven Reprogramming in Melanoma Brain Metastasis Development	Moffitt	Keiran Smalley	139,338
Sharma B	FLDOH Biomed Res Program	JEKRP 6JK01	3/19/16	8/28/19	Nanoparticle-based Targeting of MIR183 for Immunotherapy of Lung Cancer	Moffitt	Julie Djeu	342,037
Shenkman E	PCORI	CDRN-1501-26692	10/1/15	9/30/18	OneFlorida Clinical Research Consortium Phase II	Sylvester	Nicholas Tsinoremas	8,470,517
Shenkman E	NIH-OD	OT2 OD025285	8/26/17	6/30/22	South-East Enrollment Center (SEEC)	Sylvester	Stephan Zuchner	5,665,550
Trevino, J	FLDOH Biomed Res Program	JEKRP 8JK02	5/1/18	6/30/21	The Florida Pancreas Collaborative Next-Generation Biobank: Reducing Health Disparities and Improving Survival for Pancreatic Cancer	Moffitt	Jennifer Permuth	119,126

UF Total Funding	15,835,954
------------------	------------

Sylvester

Sylvester researchers collaborated on 10 funded research projects with members of UF Health and Moffitt through the FACCA pilot funding mechanism from 2017-2019. To date, these collaborations plus the 7 collaborative grants from 2015 and 2016 have resulted in 10 publications and four grants (an NCI R37, 2 Florida Biomedical Bankhead Coley awards, and a VA award) directly related to these projects. Once projects are completed, they can take years to develop into new grants and publication. Thus, the impact of the pilot funding is ongoing and are likely to have their greatest resulting impact in the next period. The table below summarizes the collaborative FACCA pilots involving Sylvester and outcomes to date:

Table 5. Sylvester Collaborative FACCA Pilot Projects

Award Number	Investigators	Project Title
FACCA-2019-02	Schatz, Jonathan (Sylvester) Davila, Marco (Moffitt)	Determinants of response to CAR-T cellular immunotherapy in aggressive B-cell lymphomas
FACCA-2019-03	Wang, Gaofeng (Sylvester) Smalley, Keiran (Moffitt)	Epigenetically reversing BRAF inhibitor resistance in melanoma by vitamin C
FACCA-2019-04	Ayad, Nagi (Sylvester)Kladde, Michael (UF Health)	Epigenetic basis of glioblastoma chemoresistance
FACCA-2019-01	Xu, Michael (Sylvester) Lele, Tanmay (UF Health)	Nuclear envelope defect and generation of micronuclei in ovarian cancer development and immune therapy
FACCA-2018-02	Kobetz, Erin (Sylvester) Wilkie, Diana (UF Health) Vadaparampil, Susan (Moffitt)	FACCA - Disparities Think Tank
FACCA-2018-01	Abreu, Maria (Sylvester) Jobin, Christian (UF Health) Pierce, Christine (Moffitt)	Role of intestinal microbiota in lung cancer therapy
FACCA-2017-15	Merchant, Nipun (Sylvester) Trevino, Jose (UF Health) Permeth, Jenny (Moffitt) Malafa, Mokenge (Moffitt)	The Florida pancreas collaborative: A partnership dedicated to the prevention and early detection of pancreatic cancer
<p>Outcomes:</p> <ol style="list-style-type: none"> Permeth JB, Trevino J, Merchant N and Malafa M. Partnering to advance early detection and prevention efforts for pancreatic cancer: the Florida Pancreas Collaborative. <i>Future Oncol.</i> 2016. Permeth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M, On Behalf Of The Florida Pancreas Collaborative. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. <i>Oncotarget.</i> 2016 Dec 27;7(52):85785-85797 doi: 10.18632/oncotarget.11768. PMID: 27589689 Permeth JB, Choi JW, Chen D, Jiang K, DeNicola G, Li J, Coppola D, Centeno BA, Magliocco A, Balagurunathan Y, Merchant N, Trevino JG, Jeong D. A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? <i>Can Bio & Med.</i> 2017 Feb 15;14(1):66-73) Permeth JB, Chen D, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth F, Trevino JG, Merchant N, Magliocco, Malafa MP, Gillies R. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Sci Rep.</i> 2017 Sep 5;7(1):10484. doi: 10.1038/s41598-017-09754-5. PMID: 28874676 Permeth J, Clark Daly A, Jeong D, Choi J, Cameron M, Chen D, Teer J, Barnett T, Li J, Powers B, Kumar N, George T, Ali K, Huynh T, Vyas S, Gwede C, Simmons V, Hodul P, Carballido E, Judge A, Fleming J, Merchant N, Trevino J. (2019) Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. <i>Cancer Med</i> 8(6):3314-3324. PMID: 31074202 PMC ID: PMC6558500 <p>NCI R01 CA229810 (MPIs Jennifer Permeth & Daniel Jeong) "Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology"; 7/1/19-6/30/24; \$4,148,118 total project costs</p>		
FACCA-2017-10	Jones, Patricia (Sylvester) Shenkman, Elizabeth (UF Health) Giuliano, Anna (Moffitt)	Florida Increases Rates of Screening and Treatment of Hepatitis C Virus (FIRST HCV)

Outcomes:		
<ol style="list-style-type: none"> 1. Kasting M, Giuliano A, Reich R, Roetzheim R, Duong L, Thomas E, Nelson D, Shenkman E, Vadaparampil S. (2019) Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. <i>Cancer Epidemiol</i> (60):112-120. PMID: 30953971 PMC ID: PMC6527446 2. Kasting M, Giuliano A, Reich R, Roetzheim R, Nelson D, Shenkman E, Vadaparampil S. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. <i>Cancer Epidemiol. Biomarkers Prev.</i> 27(4):503-513. PMID: 29588306 PMC ID: PMC5884715 		
FACCA-2017-16	Schlumbrecht, Matthew (Sylvester) Seay, Julie (Sylvester) Markham, Merry Jennifer (UF Health) Hicks, Amanda (UF Health) Quinn, Gwendolyn (Moffitt) Schabath, Matthew (Moffitt)	Developing Provider-Focused LGBT Communication Skill Building for Oncologists
Outcomes:		
<ol style="list-style-type: none"> 1. Seay J, Hicks A, Markham MJ, Schlumbrecht M, Bowman-Curci M, Woodard J, Duarte LF, Quinn GP, Schabath MB. Web-based LGBT cultural competency training intervention for oncologists: Pilot study results. <i>Cancer</i>. 2019 Sep 16. doi: 10.1002/cncr.32491. PMID: 31524952 2. Seay J, Hicks A, Markham MJ, Schlumbrecht M, Bowman M, Woodard J, Kollefrath A, Diego D, Quinn GP, Schabath MB. Developing a web-based LGBT cultural competency training for oncologists: The COLORS training. <i>Patient Educ Couns</i>. 2019 Jan 7. pii: S0738-3991(18)30531-7. doi: 10.1016/j.pec.2019.01.006. PMID: 30642714 		
FACCA-2017-01	Noriyuki, Kasahara (Sylvester) Forsyth, Peter (Moffitt)	Virotherapy combination strategy for glioblastoma

Collaborations between Sylvester, Moffitt, and UF Health members extends beyond the collaborative pilot projects supported through the State Appropriation. Projects include 11 projects active during the reporting period. 6 of the projects have peer-reviewed funded grants and 5 are clinical trials. The projects funded outside of the state appropriation represent additional funds brought into the state, broad state-wide collaboration, and the seeding of collaborations bringing innovative clinical trials to the patients of the State of Florida.

Table 6. Sylvester Active Collaborations on Peer-Reviewed Research Projects

PIs	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Sylvester Total Funding
Carrasquillo, O. / Hogan, William & Shenkman, Elizabeth (University of Florida) /	NIH-OD	1-OT2-OD-026551-01	7/20/2018	6/30/2023	South-East Enrollment Center (SEEC)	168,395
Harbour, W.	Florida Biomedical Research Program / Subcontract H. Lee Moffitt Cancer Center	7BC05	4/12/2017	2/29/2020	Defining and Targeting Aberrant Chromatin Function in Uveal Melanoma	127,363
Pollack, A. / Gillies, Robert (H. Lee Moffitt Cancer Center	NIH-NCI	5-R01-CA-190105-04 (NCE)	9/19/2014	8/31/2019	(PQC4) Habitats in Prostate Cancer	52,827
Pollack, A.	Florida Biomedical Research Program / Subcontract H. Lee Moffitt Cancer Center	6JK06	3/21/2016	2/28/2019	Biobank for African American Prostate Cancer Research in Florida	26,205
Williams, S.L. / Egan, Kathleen M. (Moffitt Cancer Center)	NIH-NCI	5-R21-CA-216227-02	5/11/2017	4/30/2019	Sequence Variation in MTDNA and Extreme Survival in Glioblastoma	47,479
Merchant, N.B.	Florida Biomedical Research Program / Subcontract H. Lee Moffitt Cancer Center	8JK02	5/1/2018	6/30/2020	The Florida Pancreas Collaborative Next Generation Biobank: Reducing Health Disparities and Improving Survival for Pancreatic Cancer	4,593
Trucco, M./Barredo, J.C.	Pediatric Cancer Foundation / Subcontract H. Lee Moffitt Cancer Center	MCC16962	9/20/2012	6/17/2019	Phase I Trial of Dose Escalation of Metformin in Combination with VIT in Children with Relapsed or Refractory Solid Tumors	21,669
Trucco, M./Barredo, J.C.	Pediatric Cancer Foundation / Subcontract H. Lee Moffitt Cancer Center	MCC17319	11/1/2014	10/31/2019	Personalized Medicine: Pediatric Total Cancer Care Protocol	9,815
Trucco, M./Barredo, J.C.	Pediatric Cancer Foundation / Subcontract H. Lee Moffitt Cancer Center	MCC18613	3/28/2017	3/27/2021	Phase II Study of Nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults	4,750
Pollack, A.	Patient-Centered Outcomes Research Institute / Subcontract University of Florida	NCT03561220	7/1/2019	3/30/2021	A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)	30,357
Barredo, J.C.	Pediatric Cancer Foundation / Subcontract Moffitt Cancer Center	MCC18613	3/28/2017	3/27/2021	Phase II Study of Nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults	4,750
					Total	526,537

Publications

Moffitt

From 2017-2019, Moffitt researchers published over 3,400 peer-reviewed publications. Of which, 98 were with collaborators at Moffitt and Sylvester. Of these collaborative inter-institutional publications, 37% were with Sylvester researchers, 54% were with UF Health researchers, and 9% involved researchers at all three centers. The table below summarizes the publications between 2017 and 2019. Attachment 1 provides the publication details.

Table 7. Collaborative Publications Involving UF Health Researchers

	# Collaborative Publications Moffitt-UF Health	# Collaborative Publications Moffitt-Sylvester	# Collaborative Publications Moffitt-Sylvester-UF Health	Total Publications by Year
2019	22	16	6	44
2018	21	10	0	31
2017	10	10	3	23
TOTALS	53	36	9	98

UF Health

During the reporting period UF Health researchers published a total of 1,198 peer-reviewed publications. Of which, 75 were with collaborators at Moffitt or Sylvester. Of these collaborative inter-institutional publications, 17% were with Sylvester researchers, 70% were with Moffitt researchers, and 12% involved researchers' at all three centers. The table below summarizes the publications between 2017 and 2019. Attachment 1 provides the publication details.

Table 8. Collaborative Publications Involving UF Health Researchers

	# Collaborative Publications Sylvester-UF	# Collaborative Publications Moffitt-UF	# Collaborative Publications Sylvester-Moffitt-UF	Total Publications by Year
2019	5	22	6	33
2018	4	21	0	25
2017	4	10	3	17
TOTALS	13	53	9	75

Sylvester

During the reporting period Sylvester researchers published a total of 847 peer-reviewed publications., of which, 58 were with collaborators at Moffitt or UF. Of these collaborative inter-institutional publications, 22% were with UF researchers, 62% were with Moffitt researchers, and 16% involved researchers at all three centers. The table below summarizes the publications between 2017 and 2019. Attachment 1 provides the publication details.

Table 9. Collaborative Publications Involving Sylvester Researchers

	# Collaborative Publications Sylvester-UF Health	# Collaborative Publications Sylvester-Moffitt	# Collaborative Publications Sylvester-UF Health-Moffitt	Total Publications by Year
--	--	--	--	----------------------------

2019	5	16	6	27
2018	4	10	0	14
2017	4	10	3	17
TOTALS	13	36	9	58

Retreats & Think Tanks

The three centers have active collaborations and have regular meetings/conferences/and retreats to facilitate ongoing collaborations and stimulate new ones among the research communities across the centers. This level of collaboration demonstrates state-wide progress in addressing the needs of Florida citizens, but also developing a destination for medical tourism for cancer patients.

A 2020 retreat, being hosted by UF Health, is being planned in Gainesville. Plans are also underway for an Immunotherapy focused think tank hosted by Moffitt and an Epigenetics focused think tank hosted by Sylvester. Originally both the retreat and think tanks were planned for early summer, but due to the COVID-19 pandemic, the events were pushed back and the centers are now targeting fall of 2020.

The table below illustrates the active work among the centers to ensure opportunities are available to foster inter-institutional collaborations. Agendas from the completed meetings and retreats are provided as Attachment 2.

Table 10. Collaborative Meetings/Retreats

Event	Date	Location	Organizing Center
2017 FACCA Annual Research Retreat	April 18-19, 2017	Lake Nona, FL	UF Health
Microbiome Think Tank Retreat	January 22-23, 2018	Gainesville, FL	UF Health
2018 FACCA Annual Research Retreat	May 2-3, 2018	Tampa, FL	Moffitt
Disparities Think Tank Retreat	May 3, 2018	Tampa, FL	Sylvester
2019 FACCA Annual Research Retreat	June 13-14, 2019	Miami, FL	Sylvester
2020 FACCA Annual Research Retreat*	TBD	Gainesville, FL	UF Health
Immunotherapy Think Tank Retreat*	TBD	TBD	Moffitt
Epigenetics Think Tank Retreat*	TBD	TBD	Sylvester
2020 Semi-Annual Director's Meeting*	October 11-13, 2020	Kansas City, KS	UF Health

* Active planning underway in collaboration among the centers

An outcome of the 2017 Directors Retreat was the agreement to pursue additional strategies to stimulate research collaborations. The decision was made to target groups of investigators for developing scientific projects building on each Centers' strengths on 4 research areas that include: (1) the Microbiome; (2) Disparities; (3) Immunotherapy; and, (4) Epigenetics. Anticipated outcomes of these projects include pioneering and practice-changing ways to better meet the cancer burden of Floridians, collaborative peer-reviewed publications, and multi-PI peer-reviewed grants.

Table 11. 2018 Funded Think Tank Applications

Moffitt PI	UF Health PI	Sylvester PI	Project Title

Pierce, Christine, PhD	Jobin, Christian, PhD*	Abreu, Maria, MD	Role of intestinal microbiota in lung cancer therapy
Vadaparampil, Susan, PhD	Wilkie, Diana, PhD	Kobetz, Erin, PhD*	FACCA Disparities Think Tank

* Indicates Contact PI from Lead Center

In response to the recent COVID-19 pandemic, the UF Health Cancer Center (UFHCC) modified how the center's two seminar series (Grand Rounds and Topics) are conducted by taking both online as virtual seminars. Recently, it was proposed to the Directors of the centers to establish a monthly online seminar series available for the entire research communities at the centers to participate, both in person and virtually. The host center and speaker will rotate among the centers monthly. Work is underway to actively integrate this new initiative into the three center's seminar schedules, with the inaugural seminar scheduled for broadcast in early fall, 2020.

Summary

Over the last three years the people of the State of Florida, as well as each Center, have benefitted from the NCI Cancer Center's program, which has provided vital resources for meeting the program's purpose of achieving and maintaining three NCI designated centers, most notably the designation of Sylvester in 2019. As demonstrated here, the program has also importantly improved scientific collaboration between the centers to benefit the state through leveraging strengths at each center to maximize impact, as exemplified by the Florida Pancreatic Initiative. Over the next three years, momentum is expected to continue as each Center continues to build upon its success bring the best and brightest to Florida to lead the nation in cancer research to benefit its citizens.

Attachment 1: Collaborative Publications

Moffitt Collaborative Publications (2017 – 2019)

	# Collaborative Publications Moffitt-UF Health	# Collaborative Publications Moffitt-Sylvester	# Collaborative Publications Moffitt-Sylvester-UF Health	Total Publications by Year
2019	22	16	6	44
2018	21	10	0	31
2017	10	10	3	23
TOTALS	53	36	9	98

Selected Collaborative Publications

2019

Moffitt-UF Health

1. Wang K, Gerke T, Chen X, Prosperi M. (2019) Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. *Cancer Med* 8(17):7399-7407. PMID: 31595713
2. Fisher B, Zaoutis T, Dvorak C, Nieder M, Zerr D, Wingard J, Callahan C, Villaluna D, Chen L, Dang H, Esbenshade A, Alexander S, Wiley J, Sung L. (2019) Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. *JAMA* 322(17):1673-1681. PMID: 31688884
3. DeFilipp Z, Ancheta R, Liu Y, Hu Z, Gale R, Snyder D, Schouten H, Kalaycio M, Hildebrandt G, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie M, Hossain N, Kharfan-Dabaja M, Hamadani M, Reshef R, Bajel A, Schultz K, Gadalla S, Gerds A, Liesveld J. (2019) Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. *Biol. Blood Marrow Transplant*. PMID: 31669399
4. Lutfi F, Skelton Iv W, Wang Y, Rosenau E, Farhadfar N, Murthy H, Cogle C, Brown R, Hiemenz J, Wingard J, Norkin M. (2019) Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. *Hematol Oncol Stem Cell Ther*. PMID: 31629722
5. U7yt6Solomon S, St Martin A, Shah N, Fatobene G, Al Malki M, Ballen K, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein C, DeFilipp Z, Champlin R, Fuchs E, Hamadani M, Hematti P, Kanakry C, McGuirk J, McNiece I, Ciurea S, Pasquini M, Rocha V, Romee R, Patel S, Vasu S, Waller E. (2019) Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. *Blood Adv* 3(19):2836-2844. PMID: 31582392 PMC ID: PMC6784523
6. Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence H, Beato F, Kang Y, Kim M, Delitto A, Underwood P, Fleming J, Trevino J, Hamilton A, Sebt S. (2019) Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. *Clin. Cancer Res*. 25(19):5984-5996. PMID: 31227505
7. Ustun C, Kim S, Chen M, Beitinjaneh A, Brown V, Dahi P, Daly A, Diaz M, Freytes C, Ganguly S, Hashmi S, Hildebrandt G, Lazarus H, Nishihori T, Olsson R, Page K, Papanicolaou G, Saad A, Seo S, William B, Wingard J, Wirk B, Yared J, Perales M, Auletta J. (2019) Increased overall and bacterial infections

following myeloablative allogeneic HCT for patients with AML in CR1. *Blood Adv* 3(17):2525-2536. PMID: 31471322 PMC ID: PMC6737406

8. Strojan P, Hernandez-Prera J, Beitler J, Eisbruch A, Saba N, Mendenhall W, Nieto C, Smee R, Rinaldo A, Ferlito A. (2019) Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis. *Cancer Treat. Rev.* 78:42-51. PMID: 31437725
9. Rashidi A, Hamadani M, Zhang M, Wang H, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt V, Bolaños-Meade J, Byrne M, Cahn J, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz M, Farhadfar N, Gale R, Ganguly S. (2019) Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Adv* 3(12):1826-1836. PMID: 31201170 PMC ID: PMC6595262
10. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz M, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes C, Gale R, Ganguly S, Hildebrandt G, Holmberg L, Kamble R, Kapoor P, Lazarus H, Lee C, Murthy H, Naik S, Nishihori T, Saad A, Savani B. (2019) Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. *Biol. Blood Marrow Transplant.* 25(6):1099-1106. PMID: 30794931 PMC ID: PMC6559839
11. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale G, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini M, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E. (2019) Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant.* 54(5):662-673. PMID: 30531954
12. Holtzman A, Bryant C, Mendenhall N, Mendenhall W, Nichols R, Henderson R, Figura N, Morris C, Williams C, Li Z, Hoppe B. (2019) Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. *Radiother Oncol* 134:204-210. PMID: 31005217
13. Kellish P, Shabashvili D, Rahman M, Nawab A, Gujjarro M, Zhang M, Cao C, Moussatche N, Boyle T, Antonia S, Reinhard M, Hartzell C, Jantz M, Mehta H, McFadden G, Kaye F, Zajac-Kaye M. (2019) Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. *J. Clin. Invest.* 130:2279-2292. PMID: 31033480 PMC ID: PMC6546459
14. Komrokji R, Al Ali N, Padron E, Cogle C, Tinsley S, Sallman D, Lancet J, Lis A. (2019) Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del (5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. *Clin Lymphoma Myeloma Leuk* 19(4):251-254. PMID: 30852241
15. Cavallari L, Van Driest S, Prows C, Bishop J, Limdi N, Pratt V, Ramsey L, Smith D, Tuteja S, Duong B, Hicks J, Lee J, Obeng A, Beitelshes A, Bell G, Blake K, Crona D, Dressler L, Gregg R, Hines L, Scott S, Shelton R, Weitzel K, Johnson J, Peterson J. (2019) Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. *Genet. Med.* PMID: 30894703
16. Mendenhall W, Strojan P, Beitler J, Langendijk J, Suarez C, Lee A, Rinaldo A, Rodrigo J, Smee R, Eisbruch A, Harrison L, Corry J, Ferlito A. (2019) Radiotherapy for parapharyngeal space tumors. *Am J Otolaryngol* 40(2):289-291. PMID: 30621929
17. Kumar A, Drusbosky L, Meacham A, Turcotte M, Bhargav P, Vasista S, Usmani S, Pampana A, Basu K, Tyagi A, Lala D, Rajagopalan S, Birajdar S, Alam A, Ghosh Roy K, Abbasi T, Vali S, Sengar M, Chinnaswamy G, Shah B, Cogle C. (2019) Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. *Leuk. Res.* 78:3-11. PMID: 30641417
18. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale G, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini M, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E. (2019) Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant

Complications Working Party of the European Society of Blood and Marrow Transplantation. *Biol. Blood Marrow Transplant.* 25(2):e46-e54. PMID: 30481594 PMC ID: PMC6362842

19. Abidi M, Hari P, Chen M, Kim S, Battiwala M, Dahi P, Diaz M, Gale R, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill J, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk B, Auletta J. (2019) Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. *Bone Marrow Transplant.* PMID: 30696997
20. Epperla N, Ahn K, Litovich C, Ahmed S, Battiwalla M, Cohen J, Dahi P, Farhadfar N, Farooq U, Freytes C, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja M, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A. (2019) Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. *J Hematol Oncol* 12(1):6. PMID: 30630534 PMC ID: PMC6329157
21. Lengacher C, Reich R, Paterson C, Shelton M, Shivers S, Ramesar S, Pleasant M, Budhrani-Shani P, Groer M, Post-White J, Johnson-Mallard V, Kane B, Cousin L, Moscoso M, Romershausen T, Park J. (2019) A Large Randomized Trial: Effects of Mindfulness-Based Stress Reduction (MBSR) for Breast Cancer (BC) Survivors on Salivary Cortisol and IL-6. *Biol Res Nurs* 21(1):39-49. PMID: 30079756
22. Emmons M, Faião-Flores F, Sharma R, Thapa R, Messina J, Becker J, Schadendorf D, Seto E, Sondak V, Koomen J, Chen Y, Lau E, Wan L, Licht J, Smalley K. (2019) HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. *Cancer Res.* 79(11):2947-2961. PMID: 30987999 PMC ID: PMC6548652

Moffitt-Sylvester

1. Ustun C, Young JAH, Papanicolaou GA, Kim S, Ahn KW, Chen M, Abdel-Azim H, Aljurf M, Beitinjaneh A, Brown V, Cerny J, Chhabra S, Kharfan-Dabaja MA, Dahi PB, Daly A, Dandoy CE, Dvorak CC, Freytes CO, Hashmi S, Lazarus H, Ljungman P, Nishihori T, Page K, Pingali SRK, Saad A, Savani BN, Weisdorf D, Williams K, Wirk B, Auletta JJ, Lindemans CA, Komanduri K, Riches M. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation.* 2019;54(8):1254-65. doi: 10.1038/s41409-018-0401-4. PubMed PMID: WOS:000479117700010.
2. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients \geq 65 years with non-Hodgkin lymphoma: a time-trend analysis. *Blood Cancer Journal.* 2019;9. doi: 10.1038/s41408-019-0261-1. PubMed PMID: WOS:000502873800001.
3. Rudra S, Jiang NM, Rosenberg SA, Olsen JR, Roach MC, Wan LP, Portelance L, Mellon EA, Bruynzeel A, Lagerwaard F, Bassetti MF, Parikh PJ, Lee PP. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. *Cancer Medicine.* 2019;8(5):2123-32. doi: 10.1002/cam4.2100. PubMed PMID: WOS:000469272500017.
4. Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang RX, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Razak ARA, Wilky B, Iyengar M, Trivedi T, Van Winkle E, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. *Journal for Immunotherapy of Cancer.* 2019;7(1). doi: 10.1186/s40425-019-0762-2. PubMed PMID: WOS:000493082200002.

5. Permath JB, Daly AC, Jeong D, Choi JW, Cameron ME, Chen DT, Teer JK, Barnett TE, Li JN, Powers BD, Kumar NB, George TJ, Ali KN, Huynh T, Vyas S, Gwede CK, Simmons VN, Hodul PJ, Carballido EM, Judge AR, Fleming JB, Merchant N, Trevino JG, Florida Pancreas C. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. *Cancer Medicine*. 2019;8(6):3314-24. doi: 10.1002/cam4.2180. PubMed PMID: WOS:000474292100059.
6. Palta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N, Parekh A, Patton C, Pepek JM, Salama JK, Tuli R, Koong AC. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*. 2019;9(5):322-32. doi: 10.1016/j.prro.2019.06.016. PubMed PMID: WOS:000483978300016.
7. Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoefflich KP, Shi HL, Wolf BB, Kang YK. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. *Cancer Discovery*. 2019;9(12):1696-707. doi: 10.1158/2159-8290.Cd-19-0555. PubMed PMID: WOS:000500270700023.
8. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorrow ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfani-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. *Clinical Cancer Research*. 2019;25(16):5143-55. doi: 10.1158/1078-0432.Ccr-18-3988. PubMed PMID: WOS:000481912400030.
9. Kasting ML, Giuliano AR, Reich RR, Roetzheim RG, Duong LM, Thomas E, Nelson DR, Shenkman E, Vadaparampil ST. Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. *Cancer Epidemiology*. 2019;60:112-20. doi: 10.1016/j.canep.2019.03.007. PubMed PMID: WOS:000468123300017.
10. Goncalves J, Emmons MF, Faiao-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM. Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell & Melanoma Research*. 2019. doi: 10.1111/pcmr.12849. PubMed PMID: WOS:000500949800001.
11. Falahat R, Perez-Villarroel P, Mailloux AW, Zhu GY, Pilon-Thomas S, Barber GN, Mule JJ. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. *Cancer Immunology Research*. 2019;7(11):1837-48. doi: 10.1158/2326-6066.Cir-19-0229. PubMed PMID: WOS:000494359300010.
12. Faiao-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM. HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clinical Cancer Research*. 2019;25(18):5686-701. doi: 10.1158/1078-0432.Ccr-18-3382. PubMed PMID: WOS:000487704400027.
13. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfani-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A,

Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. *Journal of Hematology & Oncology*. 2019;12. doi: 10.1186/s13045-018-0696-z. PubMed PMID: WOS:000455459800001.

14. Byrne MM, Thurer RJ, Studts JL. Individual decision making about lung cancer screening: A conjoint analysis of perspectives among a high-risk national sample. *Cancer Medicine*. 2019;8(12):5779-86. doi: 10.1002/cam4.2445. PubMed PMID: WOS:000479310600001.
15. Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management Across Settings An ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings. *Clinical Journal of Oncology Nursing*. 2019;23(2):27-34. doi: 10.1188/19.Cjon.S1.27-34. PubMed PMID: WOS:000461477600005.
16. Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahi PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk BM, Auletta J, Lindemans C, Riches M. Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. *Bone Marrow Transplantation*. 2019;54(8):1354-60. doi: 10.1038/s41409-019-0457-9. PubMed PMID: WOS:000479117700022.

Moffitt-Sylvester-UF Health

1. Gonçalves J, Emmons M, Faião-Flores F, Aplin A, Harbour J, Licht J, Wink M, Smalley K. (2019) Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell Melanoma Res*. PMID: 31758842
2. Zhao N, Peacock S, Lo C, Heidman L, Rice M, Fahrenholtz C, Greene A, Magani F, Copello V, Martinez M, Zhang Y, Daaka Y, Lynch C, Burnstein K. (2019) Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. *Sci Transl Med* 11(498). PMID: 31243151
3. Faião-Flores F, Emmons M, Durante M, Kinose F, Saha B, Fang B, Koomen J, Chellappan S, Maria-Engler S, Rix U, Licht J, Harbour J, Smalley K. (2019) HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clin. Cancer Res*. PMID: 31227503
4. Kasting M, Giuliano A, Reich R, Roetzheim R, Duong L, Thomas E, Nelson D, Shenkman E, Vadaparampil S. (2019) Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. *Cancer Epidemiol* (60):112-120. PMID: 30953971 PMC ID: PMC6527446
5. Permuth J, Clark Daly A, Jeong D, Choi J, Cameron M, Chen D, Teer J, Barnett T, Li J, Powers B, Kumar N, George T, Ali K, Huynh T, Vyas S, Gwede C, Simmons V, Hodul P, Carballido E, Judge A, Fleming J, Merchant N, Trevino J. (2019) Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. *Cancer Med* 8(6):3314-3324. PMID: 31074202 PMC ID: PMC6558500
6. Seay J, Hicks A, Markham M, Schlumbrecht M, Bowman M, Woodard J, Kollefrath A, Diego D, Quinn G, Schabath M. (2019) Developing a web-based LGBT cultural competency training for oncologists: The COLORS training. *Patient Educ Couns*. PMID: 30642714

2018

Moffitt-UF Health

1. Gopalan P, Villegas A, Cao C, Pinder-Schenck M, Chiappori A, Hou W, Zajac-Kaye M, Ivey A, Kaye F. (2018) CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is

synergistic with mTOR inhibition. *Oncotarget* 9(100):37352-37366. PMID: 30647837 PMC ID: PMC6324768

2. Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang R, Ayaz M, Lawrence H, Kennedy P, Sebti S. (2018) GSK3 suppression upregulates β -catenin and c-Myc to abrogate KRas-dependent tumors. *Nat Commun* 9(1):5154. PMID: 30514931 PMC ID: PMC6279809
3. Gerber M, Underwood P, Judge S, Delitto D, Delitto A, Nosacka R, DiVita B, Thomas R, Permut J, Hughes S, Wallet S, Judge A, Trevino J. (2018) Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. *Int J Mol Sci* 19(12). PMID: 30513792 PMC ID: PMC6321633
4. Wang K, Chen X, Gerke T, Bird V, Ghayee H, Prosperi M. (2018) BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions. *Cancer Med* 7(10):5272-5280. PMID: 30207080 PMC ID: PMC6198207
5. Ren Y, Ay A, Gerke T, Kahveci T. (2018) Identification of jointly correlated gene sets. *J Bioinform Comput Biol* 16(5):1840019. PMID: 30419787
6. Farooqi B, Modi A, Hussaini M, Markham M, Duff J. (2018) Principles for the Oncologist in Caring for Muslim Patients. *J Oncol Pract* 14(9):521-524. PMID: 30138053
7. Jim H, Sutton S, Majhail N, Wood W, Jacobsen P, Wingard J, Wu J, Knight J, Syrjala K, Lee S. (2018) Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial. *Bone Marrow Transplant*. 53(8):1038-1043. PMID: 29515249 PMC ID: PMC6064383
8. Okunieff P, Casey-Sawicki K, Lockney N, Hoppe B, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown J, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning H, Feng F, Galbraith S, Solanki A, Harkenrider M, Tuli R, Decker R, Finkelstein S, Hsu C. (2018) Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. *Clin. Cancer Res*. 24(15):3500-3509. PMID: 29661779
9. Tucker C, Wippold G, Guastello A, Arthur T, Desmond F, Rivers B, Davis J, Rivers D, Green B. (2018) Predictors of Cancer Screening Among Culturally Diverse Men. *Am J Mens Health* 12(4):837-843. PMID: 27118456 PMC ID: PMC6131431
10. Hashmi S, Lee S, Savani B, Burns L, Wingard J, Perales M, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri K, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton B, Majhail N, Kharfan-Dabaja M, Schriber J. (2018) ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. *Biol. Blood Marrow Transplant*. 24(6):1119-1124. PMID: 29608957
11. Yaghjian L, Rich S, Mao L, Mai V, Egan K. (2018) Interactions of coffee consumption and postmenopausal hormone use in relation to breast cancer risk in UK Biobank. *Cancer Causes Control* 29(6):519-525. PMID: 29651651
12. Kowalski A, Striley C, Varma D, Egan K, Yaghjian L. (2018) Interactions between Alcohol Consumption and Adjuvant Hormone Therapy in Relation to Breast Cancer-Free Survival. *J Breast Cancer* 21(2):158-164. PMID: 29963111 PMC ID: PMC6015986
13. Buchbinder D, Kelly D, Duarte R, Auletta J, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah A, Ahmed I, Atsuta Y, Basak G, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale R, Galvin J, Hamadani M. (2018) Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant*. 53(5):535-555. PMID: 29343837 PMC ID: PMC5985976
14. Volpi S, Bult C, Chisholm R, Deverka P, Ginsburg G, Jacob H, Kasapi M, McLeod H, Roden D, Williams M, Green E, Rodriguez L, Aronson S, Cavallari L, Denny J, Dressler L, Johnson J, Klein T, Leeder J, Piquette-

- Miller M, Perera M, Rasmussen-Torvik L, Rehm H, Ritchie M, Skaar T. (2018) Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. *Clin. Pharmacol. Ther.* 103(5):778-786. PMID: 29460415 PMC ID: PMC5902434
15. Mosley S, Hicks J, Portman D, Donovan K, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langae T, Clare-Salzler M, Starostik P, Chang Y, Rajasekhara S, Smith J, Soares H, George T, McLeod H, Cavallari L. (2018) Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. *Contemp Clin Trials* 68():7-13. PMID: 29535047 PMC ID: PMC5899651
 16. Kahen E, Brohl A, Yu D, Welch D, Cubitt C, Lee J, Chen Y, Yoder S, Teer J, Zhang Y, Wallace M, Reed D. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. *Oncotarget* 9(32):22571-22585. PMID: 29854299 PMC ID: PMC5978249
 17. Shah N, Ahn K, Litovich C, Fenske T, Ahmed S, Battiwalla M, Bejanyan N, Dahi P, Bolaños-Meade J, Chen A, Ciurea S, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera A, Haverkos B, Holmberg L, Hossain N, Khafan-Dabaja M, Kenkre V, Lazarus H, Murthy H, Nishihori T, Rezvani A. (2018) Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. *Blood Adv* 2(8):933-940. PMID: 29685953 PMC ID: PMC5916010
 18. Kasting M, Giuliano A, Reich R, Roetzheim R, Nelson D, Shenkman E, Vadaparampil S. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. *Cancer Epidemiol. Biomarkers Prev.* 27(4):503-513. PMID: 29588306 PMC ID: PMC5884715
 19. Masannat J, Purayil H, Zhang Y, Russin M, Mahmud I, Kim W, Liao D, Daaka Y. (2018) β Arrestin2 Mediates Renal Cell Carcinoma Tumor Growth. *Sci Rep* 8(1):4879. PMID: 29559707 PMC ID: PMC5861056
 20. Kelly D, Buchbinder D, Duarte R, Auletta J, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah A, Ahmed I, Atsuta Y, Basak G, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale R, Galvin J, Hamadani M. (2018) Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. *Biol. Blood Marrow Transplant.* 24(2):228-241. PMID: 28939455 PMC ID: PMC5768142
 21. Hossain F, Majumder S, Ucar D, Rodriguez P, Golde T, Minter L, Osborne B, Miele L. (2018) Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. *Front Immunol* (9):1288. PMID: 29915603 PMC ID: PMC5994797

Moffitt-Sylvester

1. Weinfurter RJ, Niell B, Mekhail Y, Aguila E, Kamat L. Specialized Second Opinion Interpretations of Breast Imaging: Impact on Additional Workup and Management. *Clinical Breast Cancer.* 2018;18(5):E1031-E6. doi: 10.1016/j.clbc.2018.03.009. PubMed PMID: WOS:000445702400040.
2. Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. *Journal of Clinical Oncology.* 2018;36(9):859-+. doi: 10.1200/jco.2017.75.5207. PubMed PMID: WOS:000429062700005.
3. Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by

- the 21-Gene Assay. *Jama Oncology*. 2018;4(1). doi: 10.1001/jamaoncol.2017.3470. PubMed PMID: WOS:000422795300001.
4. Trucco M, Barredo JC, Goldberg J, Leclerc GM, Hale GA, Gill J, Setty B, Smith T, Lush R, Lee JK, Reed DR. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin. *Pediatric Blood & Cancer*. 2018;65(9). doi: 10.1002/pbc.27224. PubMed PMID: WOS:000439863700010.
 5. Peterson SL, Husnain M, Pollack T, Pimentel A, Loaiza-Bonilla A, Westendorf-Overley C, Ratermann K, Anthony L, Desimone P, Goel G, Kudrimoti M, Dineen S, Tzeng CWD, Hosein PJ. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. *Anticancer Research*. 2018;38(7):4035-9. doi: 10.21873/anticancer.12692. PubMed PMID: WOS:000449943500031.
 6. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical Lung Cancer*. 2018;19(3):280-+. doi: 10.1016/j.clcc.2017.12.007. PubMed PMID: WOS:000430510300019.
 7. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zvirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. *Neuro-Oncology*. 2018;20(5):674-86. doi: 10.1093/neuonc/nox208. PubMed PMID: WOS:000430161300012.
 8. Lee MS, Tyson DM, Gonzalez BD, Small BJ, Lechner SC, Antoni MH, Vinard A, Krause M, Meade C, Jacobsen PB. Anxiety and depression in Spanish-speaking Latina cancer patients prior to starting chemotherapy. *Psycho-Oncology*. 2018;27(1):333-8. doi: 10.1002/pon.4462. PubMed PMID: WOS:000422995000044.
 9. Konno H, Yamauchi S, Berglund A, Putney RM, Mule JJ, Barber GN. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. *Oncogene*. 2018;37(15):2037-51. doi: 10.1038/s41388-017-0120-0. PubMed PMID: WOS:000429899400007.
 10. Hoogland AI, Lechner SC, Gonzalez BD, Small BJ, Tyson DM, Asvat Y, Barata A, Gomez MF, Rodriguez Y, Jim HSL, Antoni MH, Jacobsen PB, Meade CD. Efficacy of a Spanish-Language Self-Administered Stress Management Training intervention for Latinas undergoing chemotherapy. *Psycho-Oncology*. 2018;27(4):1305-11. doi: 10.1002/pon.4673. PubMed PMID: WOS:000430230400028.

2017

Moffitt-UF Health

1. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz M, Freytes C, Gale R, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani B, Schriber J. (2017) Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. *Bone Marrow Transplant*. 52(12):1616-1622. PMID: 28920949 PMC ID: PMC5859934
2. Wang K, Chen X, Bird V, Gerke T, Manini T, Prosperi M. (2017) Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases. *Int. J. Cancer* 141(9):1783-1793. PMID: 28699177 PMC ID: PMC6169522

3. Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson D, Robertson K, Ostrov D, Rameshwar P, Xia C, Liu C. (2017) A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. *Mol. Ther.* 25(10):2299-2308. PMID: 28865999 PMC ID: PMC5628867
4. Kumar R, Rotondo R, Bradley J, Vern-Gross T, Huh S, Indelicato D. (2017) Mid-treatment magnetic resonance imaging in pediatric intracranial low-grade gliomas treated with proton beam therapy. *Acta Oncol* 56(9):1243-1247. PMID: 28339304
5. Moriyama B, Obeng A, Barbarino J, Penzak S, Henning S, Scott S, Agúndez J, Wingard J, McLeod H, Klein T, Cross S, Caudle K, Walsh T. (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. *Clin. Pharmacol. Ther.* 102(1):45-51. PMID: 27981572 PMC ID: PMC5474211
6. Reich R, Lengacher C, Klein T, Newton C, Shivers S, Ramesar S, Alinat C, Paterson C, Le A, Park J, Johnson-Mallard V, Elias M, Moscoso M, Goodman M, Kip K. (2017) A Randomized Controlled Trial of the Effects of Mindfulness-Based Stress Reduction (MBSR[BC]) on Levels of Inflammatory Biomarkers Among Recovering Breast Cancer Survivors. *Biol Res Nurs* 19(4):456-464. PMID: 28460534 PMC ID: PMC5942506
7. Husain K, Centeno B, Coppola D, Trevino J, Sebti S, Malafa M. (2017) δ -Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. *Oncotarget* 8(19):31554-31567. PMID: 28404939 PMC ID: PMC5458229
8. Wingard J, Wood W, Martens M, Le-Rademacher J, Logan B, Knight J, Jacobsen P, Jim H, Majhail N, Syrjala K, Rizzo J, Lee S. (2017) Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). *Biol. Blood Marrow Transplant.* 23(1):161-164. PMID: 27742574 PMC ID: PMC5182134
9. Extermann M, Leeuwenburgh C, Samiian L, Sehovic M, Xu J, Cubitt C, Jacobsen P, Pahor M, Grobmyer S, Manini. (2017) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. *J Geriatr Oncol* 8(1):69-75. PMID: 27743848 PMC ID: PMC5299045
10. Reich R, Lengacher C, Alinat C, Kip K, Paterson C, Ramesar S, Han H, Ismail-Khan R, Johnson-Mallard V, Moscoso M, Budhrani-Shani P, Shivers S, Cox C, Goodman M, Park J. (2017) Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. *J Pain Symptom Manage* 53(1):85-95. PMID: 27720794

Moffitt-Sylvester

1. Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao JJ, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. *Neuro-Oncology.* 2017;19(10):1380-90. doi: 10.1093/neuonc/nox086. PubMed PMID: WOS:000410404200018.
2. Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E, Berz D. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. *Lung Cancer.* 2017;108:22-8. doi: 10.1016/j.lungcan.2017.02.010. PubMed PMID: WOS:000405261300005.
3. Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. *Lancet Oncology.* 2017;18(2):202-11. doi: 10.1016/s1470-2045(16)30648-9. PubMed PMID: WOS:000396343000046.

4. Saeed NA, Mellon EA, Meredith KL, Hoffe SE, Shridhar R, Frakes J, Fontaine JP, Pimiento JM, Kothari N, Almhanna K. Adjuvant chemotherapy and outcomes in esophageal carcinoma. *Journal of Gastrointestinal Oncology*. 2017;8(5):816-24. doi: 10.21037/jgo.2017.07.10. PubMed PMID: WOS:000413224600009.
5. Permuth JB, Choi JW, Chen DT, Jiang K, DeNicola G, Li JN, Coppola D, Centeno BA, Magliocco A, Balagurunathan Y, Merchant N, Trevino JG, Jeong D, Florida Pancreas C. A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? *Cancer Biology & Medicine*. 2017;14(1):66-73. doi: 10.20892/j.issn.2095-3941.2017.0006. PubMed PMID: WOS:000401102700007.
6. Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W, Ctr Int Blood Marrow Transplant R, Res Collaboration Natl Marrow D. Cytogenetic Risk Determines Outcomes After Allogeneic Transplantation in Older Patients With Acute Myeloid Leukemia in Their Second Complete Remission: A Center for International Blood and Marrow Transplant Research Cohort Analysis. *Cancer*. 2017;123(11):2035-42. doi: 10.1002/cncr.30567. PubMed PMID: WOS:000401841700022.
7. Mellon EA, Orman A, Joya LE, Montejo ME, Laronga C, Hoover SJ, Lee MC, Khakpour N, Kubal PF, Diaz R. Frequency of whole breast radiation therapy after intraoperative radiation therapy due to criteria identified by lumpectomy. *Brachytherapy*. 2017;16(1):174-80. doi: 10.1016/j.brachy.2016.09.012. PubMed PMID: WOS:000392793900019.
8. Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. *Acta Oncologica*. 2017;56(3):391-7. doi: 10.1080/0284186x.2016.1256497. PubMed PMID: WOS:000396774900003.
9. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellstrom-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, del Canizo C, Greenberg PL, Shammo JM, Skikne B, Yu XJ, List AF. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). *Journal of Hematology & Oncology*. 2017;10. doi: 10.1186/s13045-017-0491-2. PubMed PMID: WOS:000404058800001.
10. Chow LWC, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CYC, Loo WTY, Gluck S, Toi M. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. *Asia-Pacific Journal of Clinical Oncology*. 2017;13(6):372-8. doi: 10.1111/ajco.12682. PubMed PMID: WOS:000427541000006.

Sylvester-Moffitt-UF Health

1. Permuth J, Chen D, Yoder S, Li J, Smith A, Choi J, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno B, Klapman J, Hodul P, Karreth F, Trevino J, Merchant N, Magliocco A, Malafa M, Gillies R. (2017) Linking Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Sci Rep* 7(1):10484. PMID: 28874676 PMC ID: PMC5585319
2. Liu H, Ahn K, Hu Z, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald M, Sabloff M, Olsson R, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks D, Copelan E, Gergis U. (2017) Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biol. Blood Marrow Transplant*. 23(5):767-775. PMID: 28115276 PMC ID: PMC5590102
3. Permuth J, Choi J, Chen D, Jiang K, DeNicola G, Li J, Coppola D, Centeno B, Magliocco A, Balagurunathan Y, Merchant N, Trevino J, Jeong D. (2017) A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? *Cancer Biol Med* 14(1):66-73. PMID: 28443205 PMC ID: PMC5365183

UF Health Collaborative Publications (2017 – 2019)

	# Collaborative Publications UF Health-Sylvester	# Collaborative Publications UF Health-Moffitt	# Collaborative Publications UF Health-Sylvester-Moffitt	Total Publications by Year
2019	5	22	6	33
2018	4	21	0	25
2017	4	10	3	17
TOTALS	13	53	9	75

2019

UF Health-Sylvester

1. Luo H, Zhu G, Xu J, Lai Q, Yan B, Guo Y, Fung T, Zeisig B, Cui Y, Zha J, Cogle C, Wang F, Xu B, Yang F, Li W, So C, Qiu Y, Xu M, Huang S. (2019) HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. *Cancer Cell* 36(6):645-659.e8. PMID: 31786140 PMC ID: PMC6917035
2. Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang C, Ali A, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. (2019) A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. *Breast* 49():141-148. PM ID: 31805500
3. Carrier F, Liao Y, Mendenhall N, Guerrieri P, Todor D, Ahmad A, Dominello M, Joiner M, Burmeister J. (2019) Three Discipline Collaborative Radiation Therapy (3DCRT) Special Debate: I would treat prostate cancer with proton therapy. *J Appl Clin Med Phys* 20(7):7-14. PMID: 31166085 PMC ID: PMC6612688
4. Sundermann A, Clancy C, Pasculle A, Liu G, Cumbie R, Driscoll E, Ayres A, Donahue L, Pergam S, Abbo L, Andes D, Chandrasekar P, Galdys A, Hanson K, Marr K, Mayer J, Mehta S, Morris M, Perfect J, Revankar S, Smith B, Swaminathan S, Thompson G, Varghese M, Vazquez J. (2019) How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. *Clin. Infect. Dis.* 68(5):850-853. PMID: 30299481
5. Asfar T, Ben Taleb Z, Osibogun O, Ruano-Herrera E, Sierra D, Ward K, Salloum R, Maziak W. (2019) How Do Waterpipe Smoking Establishments Attract Smokers? Implications for Policy. *Subst Use Misuse* 54(4):560-571. PMID: 30430905 PMC ID: PMC6443473

UF Health-Moffitt

1. Wang K, Gerke T, Chen X, Prosperi M. (2019) Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. *Cancer Med* 8(17):7399-7407. PMID: 31595713
2. Fisher B, Zaoutis T, Dvorak C, Nieder M, Zerr D, Wingard J, Callahan C, Villaluna D, Chen L, Dang H, Esbenshade A, Alexander S, Wiley J, Sung L. (2019) Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. *JAMA* 322(17):1673-1681. PMID: 31688884
3. DeFilipp Z, Ancheta R, Liu Y, Hu Z, Gale R, Snyder D, Schouten H, Kalaycio M, Hildebrandt G, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie M, Hossain N, Kharfan-Dabaja M, Hamadani M, Reshef R, Bajel A, Schultz K, Gadalla S, Gerds A, Liesveld J. (2019) Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. *Biol. Blood Marrow Transplant.* PMID: 31669399

4. Lutfi F, Skelton Iv W, Wang Y, Rosenau E, Farhadfar N, Murthy H, Cogle C, Brown R, Hiemenz J, Wingard J, Norkin M. (2019) Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. *Hematol Oncol Stem Cell Ther.* PMID: 31629722
5. Solomon S, St Martin A, Shah N, Fatobene G, Al Malki M, Ballen K, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein C, DeFilipp Z, Champlin R, Fuchs E, Hamadani M, Hematti P, Kanakry C, McGuirk J, McNiece I, Ciurea S, Pasquini M, Rocha V, Romee R, Patel S, Vasu S, Waller E. (2019) Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. *Blood Adv* 3(19):2836-2844. PMID: 31582392 PMC ID: PMC6784523
6. Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence H, Beato F, Kang Y, Kim M, Delitto A, Underwood P, Fleming J, Trevino J, Hamilton A, Sebti S. (2019) Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. *Clin. Cancer Res.* 25(19):5984-5996. PMID: 31227505
7. Ustun C, Kim S, Chen M, Beitinjaneh A, Brown V, Dahi P, Daly A, Diaz M, Freytes C, Ganguly S, Hashmi S, Hildebrandt G, Lazarus H, Nishihori T, Olsson R, Page K, Papanicolaou G, Saad A, Seo S, William B, Wingard J, Wirk B, Yared J, Perales M, Auletta J. (2019) Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. *Blood Adv* 3(17):2525-2536. PMID: 31471322 PMC ID: PMC6737406
8. Strojan P, Hernandez-Prera J, Beitler J, Eisbruch A, Saba N, Mendenhall W, Nieto C, Smee R, Rinaldo A, Ferlito A. (2019) Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis. *Cancer Treat. Rev.* 78:42-51. PMID: 31437725
9. Rashidi A, Hamadani M, Zhang M, Wang H, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt V, Bolaños-Meade J, Byrne M, Cahn J, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz M, Farhadfar N, Gale R, Ganguly S. (2019) Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Adv* 3(12):1826-1836. PMID: 31201170 PMC ID: PMC6595262
10. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz M, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes C, Gale R, Ganguly S, Hildebrandt G, Holmberg L, Kamble R, Kapoor P, Lazarus H, Lee C, Murthy H, Naik S, Nishihori T, Saad A, Savani B. (2019) Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. *Biol. Blood Marrow Transplant.* 25(6):1099-1106. PMID: 30794931 PMC ID: PMC6559839
11. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale G, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini M, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E. (2019) Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant.* 54(5):662-673. PMID: 30531954
12. Holtzman A, Bryant C, Mendenhall N, Mendenhall W, Nichols R, Henderson R, Figura N, Morris C, Williams C, Li Z, Hoppe B. (2019) Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. *Radiother Oncol* 134:204-210. PMID: 31005217
13. Kellish P, Shabashvili D, Rahman M, Nawab A, Guijarro M, Zhang M, Cao C, Moussatche N, Boyle T, Antonia S, Reinhard M, Hartzell C, Jantz M, Mehta H, McFadden G, Kaye F, Zajac-Kaye M. (2019) Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. *J. Clin. Invest.* 130:2279-2292. PMID: 31033480 PMC ID: PMC6546459
14. Komrokji R, Al Ali N, Padron E, Cogle C, Tinsley S, Sallman D, Lancet J, Lis A. (2019) Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del (5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. *Clin Lymphoma Myeloma Leuk* 19(4):251-254. PMID: 30852241
15. Cavallari L, Van Driest S, Prows C, Bishop J, Limdi N, Pratt V, Ramsey L, Smith D, Tuteja S, Duong B, Hicks J, Lee J, Obeng A, Beitelshes A, Bell G, Blake K, Crona D, Dressler L, Gregg R, Hines L, Scott S,

- Shelton R, Weitzel K, Johnson J, Peterson J. (2019) Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. *Genet. Med.* PMID: 30894703
16. Mendenhall W, Strojan P, Beitler J, Langendijk J, Suarez C, Lee A, Rinaldo A, Rodrigo J, Smee R, Eisbruch A, Harrison L, Corry J, Ferlito A. (2019) Radiotherapy for parapharyngeal space tumors. *Am J Otolaryngol* 40(2):289-291. PMID: 30621929
 17. Kumar A, Drusbosky L, Meacham A, Turcotte M, Bhargav P, Vasista S, Usmani S, Pampana A, Basu K, Tyagi A, Lala D, Rajagopalan S, Birajdar S, Alam A, Ghosh Roy K, Abbasi T, Vali S, Sengar M, Chinnaswamy G, Shah B, Cogle C. (2019) Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. *Leuk. Res.* 78:3-11. PMID: 30641417
 18. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale G, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini M, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E. (2019) Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. *Biol. Blood Marrow Transplant.* 25(2):e46-e54. PMID: 30481594 PMC ID: PMC6362842
 19. Abidi M, Hari P, Chen M, Kim S, Battiwala M, Dahi P, Diaz M, Gale R, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill J, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk B, Auletta J. (2019) Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. *Bone Marrow Transplant.* PMID: 30696997
 20. Epperla N, Ahn K, Litovich C, Ahmed S, Battiwalla M, Cohen J, Dahi P, Farhadfar N, Farooq U, Freytes C, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfani-Dabaja M, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A. (2019) Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. *J Hematol Oncol* 12(1):6. PMID: 30630534 PMC ID: PMC6329157
 21. Lengacher C, Reich R, Paterson C, Shelton M, Shivers S, Ramesar S, Pleasant M, Budhrani-Shani P, Groer M, Post-White J, Johnson-Mallard V, Kane B, Cousin L, Moscoso M, Romershausen T, Park J. (2019) A Large Randomized Trial: Effects of Mindfulness-Based Stress Reduction (MBSR) for Breast Cancer (BC) Survivors on Salivary Cortisol and IL-6. *Biol Res Nurs* 21(1):39-49. PMID: 30079756
 22. Emmons M, Faião-Flores F, Sharma R, Thapa R, Messina J, Becker J, Schadendorf D, Seto E, Sondak V, Koomen J, Chen Y, Lau E, Wan L, Licht J, Smalley K. (2019) HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. *Cancer Res.* 79(11):2947-2961. PMID: 30987999 PMC ID: PMC6548652

UF Health-Sylvester-Moffitt

1. Gonçalves J, Emmons M, Faião-Flores F, Aplin A, Harbour J, Licht J, Wink M, Smalley K. (2019) Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell Melanoma Res.* PMID: 31758842
2. Zhao N, Peacock S, Lo C, Heidman L, Rice M, Fahrenholtz C, Greene A, Magani F, Copello V, Martinez M, Zhang Y, Daaka Y, Lynch C, Burnstein K. (2019) Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. *Sci Transl Med* 11(498). PMID: 31243151
3. Faião-Flores F, Emmons M, Durante M, Kinose F, Saha B, Fang B, Koomen J, Chellappan S, Maria-Engler S, Rix U, Licht J, Harbour J, Smalley K. (2019) HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clin. Cancer Res.* PMID: 31227503

4. Kasting M, Giuliano A, Reich R, Roetzheim R, Duong L, Thomas E, Nelson D, Shenkman E, Vadaparampil S. (2019) Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. *Cancer Epidemiol* (60):112-120. PMID: 30953971 PMC ID: PMC6527446
5. Permuth J, Clark Daly A, Jeong D, Choi J, Cameron M, Chen D, Teer J, Barnett T, Li J, Powers B, Kumar N, George T, Ali K, Huynh T, Vyas S, Gwede C, Simmons V, Hodul P, Carballido E, Judge A, Fleming J, Merchant N, Trevino J. (2019) Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. *Cancer Med* 8(6):3314-3324. PMID: 31074202 PMC ID: PMC6558500
6. Seay J, Hicks A, Markham M, Schlumbrecht M, Bowman M, Woodard J, Kollfrath A, Diego D, Quinn G, Schabath M. (2019) Developing a web-based LGBT cultural competency training for oncologists: The COLORS training. *Patient Educ Couns*. PMID: 30642714

2018

UF Health-Sylvester

1. Tyner J, Tognon C, Bottomly D, Wilmot B, Kurtz S, Savage S, Long N, Schultz A, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang B, Coblenz C, d'Almeida A, Cook R, Danilov A, Dao K, Degnin M. (2018) Functional genomic landscape of acute myeloid leukaemia. *Nature* 562(7728):526-531. PMID: 30333627 PMC ID: PMC6280667
2. Luo H, Wang F, Zha J, Li H, Yan B, Du Q, Yang F, Sobh A, Vulpe C, Drusbosky L, Cogle C, Chepelev I, Xu B, Nimer S, Licht J, Qiu Y, Chen B, Xu M, Huang S. (2018) CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. *Blood* 132(8):837-848. PMID: 29760161 PMC ID: PMC6107877
3. Barredo J, Hastings C, Lu X, Devidas M, Chen Y, Armstrong D, Winick N, Wood B, Yanofsky R, Loh M, Gastier-Foster J, Jorstad D, Marcus R, Ritchey K, Carrol W, Hunger S. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. *Pediatr Blood Cancer* 65(5):e26928. PMID: 29286562 PMC ID: PMC6136835
4. Swords R, Azzam D, Al-Ali H, Lohse I, Volmar C, Watts J, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers S, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle C, Wahlestedt C. (2018) Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. *Leuk. Res.* 64():34-41. PMID: 29175379 PMC ID: PMC5756519

UF Health-Moffitt

1. Gopalan P, Villegas A, Cao C, Pinder-Schenck M, Chiappori A, Hou W, Zajac-Kaye M, Ivey A, Kaye F. (2018) CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. *Oncotarget* 9(100):37352-37366. PMID: 30647837 PMC ID: PMC6324768
2. Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang R, Ayaz M, Lawrence H, Kennedy P, Sebt S. (2018) GSK3 suppression upregulates β -catenin and c-Myc to abrogate KRas-dependent tumors. *Nat Commun* 9(1):5154. PMID: 30514931 PMC ID: PMC6279809
3. Gerber M, Underwood P, Judge S, Delitto D, Delitto A, Nosacka R, DiVita B, Thomas R, Permuth J, Hughes S, Wallet S, Judge A, Trevino J. (2018) Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. *Int J Mol Sci* 19(12). PMID: 30513792 PMC ID: PMC6321633

4. Wang K, Chen X, Gerke T, Bird V, Ghayee H, Prosperi M. (2018) BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions. *Cancer Med* 7(10):5272-5280. PMID: 30207080 PMC ID: PMC6198207
5. Ren Y, Ay A, Gerke T, Kahveci T. (2018) Identification of jointly correlated gene sets. *J Bioinform Comput Biol* 16(5):1840019. PMID: 30419787
6. Farooqi B, Modi A, Hussaini M, Markham M, Duff J. (2018) Principles for the Oncologist in Caring for Muslim Patients. *J Oncol Pract* 14(9):521-524. PMID: 30138053
7. Jim H, Sutton S, Majhail N, Wood W, Jacobsen P, Wingard J, Wu J, Knight J, Syrjala K, Lee S. (2018) Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial. *Bone Marrow Transplant*. 53(8):1038-1043. PMID: 29515249 PMC ID: PMC6064383
8. Okunieff P, Casey-Sawicki K, Lockney N, Hoppe B, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown J, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning H, Feng F, Galbraith S, Solanki A, Harkenrider M, Tuli R, Decker R, Finkelstein S, Hsu C. (2018) Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. *Clin. Cancer Res.* 24(15):3500-3509. PMID: 29661779
9. Tucker C, Wippold G, Guastello A, Arthur T, Desmond F, Rivers B, Davis J, Rivers D, Green B. (2018) Predictors of Cancer Screening Among Culturally Diverse Men. *Am J Mens Health* 12(4):837-843. PMID: 27118456 PMC ID: PMC6131431
10. Hashmi S, Lee S, Savani B, Burns L, Wingard J, Perales M, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri K, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton B, Majhail N, Kharfan-Dabaja M, Schriber J. (2018) ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. *Biol. Blood Marrow Transplant*. 24(6):1119-1124. PMID: 29608957
11. Yaghjian L, Rich S, Mao L, Mai V, Egan K. (2018) Interactions of coffee consumption and postmenopausal hormone use in relation to breast cancer risk in UK Biobank. *Cancer Causes Control* 29(6):519-525. PMID: 29651651
12. Kowalski A, Striley C, Varma D, Egan K, Yaghjian L. (2018) Interactions between Alcohol Consumption and Adjuvant Hormone Therapy in Relation to Breast Cancer-Free Survival. *J Breast Cancer* 21(2):158-164. PMID: 29963111 PMC ID: PMC6015986
13. Buchbinder D, Kelly D, Duarte R, Auletta J, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah A, Ahmed I, Atsuta Y, Basak G, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale R, Galvin J, Hamadani M. (2018) Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant*. 53(5):535-555. PMID: 29343837 PMC ID: PMC5985976
14. Volpi S, Bult C, Chisholm R, Deverka P, Ginsburg G, Jacob H, Kasapi M, McLeod H, Roden D, Williams M, Green E, Rodriguez L, Aronson S, Cavallari L, Denny J, Dressler L, Johnson J, Klein T, Leeder J, Piquette-Miller M, Perera M, Rasmussen-Torvik L, Rehm H, Ritchie M, Skaar T. (2018) Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. *Clin. Pharmacol. Ther.* 103(5):778-786. PMID: 29460415 PMC ID: PMC5902434
15. Mosley S, Hicks J, Portman D, Donovan K, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langae T, Clare-Salzler M, Starostik P, Chang Y, Rajasekhara S, Smith J, Soares H, George T, McLeod H, Cavallari L. (2018) Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. *Contemp Clin Trials* 68():7-13. PMID: 29535047 PMC ID: PMC5899651
16. Kahen E, Brohl A, Yu D, Welch D, Cubitt C, Lee J, Chen Y, Yoder S, Teer J, Zhang Y, Wallace M, Reed D. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in

malignant peripheral nerve sheath tumors. *Oncotarget* 9(32):22571-22585. PMID: 29854299 PMC ID: PMC5978249

17. Shah N, Ahn K, Litovich C, Fenske T, Ahmed S, Battiwalla M, Bejanyan N, Dahi P, Bolaños-Meade J, Chen A, Ciurea S, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera A, Haverkos B, Holmberg L, Hossain N, Kharfan-Dabaja M, Kenkre V, Lazarus H, Murthy H, Nishihori T, Rezvani A. (2018) Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. *Blood Adv* 2(8):933-940. PMID: 29685953 PMC ID: PMC5916010
18. Kasting M, Giuliano A, Reich R, Roetzheim R, Nelson D, Shenkman E, Vadaparampil S. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. *Cancer Epidemiol. Biomarkers Prev.* 27(4):503-513. PMID: 29588306 PMC ID: PMC5884715
19. Masannat J, Purayil H, Zhang Y, Russin M, Mahmud I, Kim W, Liao D, Daaka Y. (2018) β Arrestin2 Mediates Renal Cell Carcinoma Tumor Growth. *Sci Rep* 8(1):4879. PMID: 29559707 PMC ID: PMC5861056
20. Kelly D, Buchbinder D, Duarte R, Auletta J, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah A, Ahmed I, Atsuta Y, Basak G, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale R, Galvin J, Hamadani M. (2018) Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. *Biol. Blood Marrow Transplant.* 24(2):228-241. PMID: 28939455 PMC ID: PMC5768142
21. Hossain F, Majumder S, Ucar D, Rodriguez P, Golde T, Minter L, Osborne B, Miele L. (2018) Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. *Front Immunol* (9):1288. PMID: 29915603 PMC ID: PMC5994797

2017

UF Health-Sylvester

1. Diaby V, Ali A, Williams K, Ezendu K, Soto-Perez-de-Celis E, Chavarri-Guerra Y, de Lima Lopes G. (2017) Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. *Breast Cancer Res. Treat.* 166(3):951-963. PMID: 28840424
2. Hardy K, Embry L, Kairalla J, Helian S, Devidas M, Armstrong D, Hunger S, Carroll W, Larsen E, Raetz E, Loh M, Yang W, Relling M, Noll R, Winick N. (2017) Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. *J. Clin. Oncol.* 35(23):2700-2707. PMID: 28671857 PMC ID: PMC5549456
3. Gea-Banacloche J, Komanduri K, Carpenter P, Paczesny S, Sarantopoulos S, Young J, El Kassar N, Le R, Schultz K, Griffith L, Savani B, Wingard J. (2017) National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. *Biol. Blood Marrow Transplant.* 23(6):870-881. PMID: 27751936 PMC ID: PMC5392182
4. Pan F, Wingo T, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega J, Wang J, Nazha A, Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips B, Huang S, Wang J, He C, Li G, Radivoyevitch T, Aifantis I, Maciejewski J. (2017) Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. *Nat Commun* 8():15102. PMID: 28440315 PMC ID: PMC5414116

UF Health-Moffitt

1. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz M, Freytes C, Gale R, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani B, Schriber J. (2017) Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. *Bone Marrow Transplant.* 52(12):1616-1622. PMID: 28920949 PMC ID: PMC5859934
2. Wang K, Chen X, Bird V, Gerke T, Manini T, Prosperi M. (2017) Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases. *Int. J. Cancer* 141(9):1783-1793. PMID: 28699177 PMC ID: PMC6169522
3. Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson D, Robertson K, Ostrov D, Rameshwar P, Xia C, Liu C. (2017) A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. *Mol. Ther.* 25(10):2299-2308. PMID: 28865999 PMC ID: PMC5628867
4. Kumar R, Rotondo R, Bradley J, Vern-Gross T, Huh S, Indelicato D. (2017) Mid-treatment magnetic resonance imaging in pediatric intracranial low-grade gliomas treated with proton beam therapy. *Acta Oncol* 56(9):1243-1247. PMID: 28339304
5. Moriyama B, Obeng A, Barbarino J, Penzak S, Henning S, Scott S, Agúndez J, Wingard J, McLeod H, Klein T, Cross S, Caudle K, Walsh T. (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. *Clin. Pharmacol. Ther.* 102(1):45-51. PMID: 27981572 PMC ID: PMC5474211
6. Reich R, Lengacher C, Klein T, Newton C, Shivers S, Ramesar S, Alinat C, Paterson C, Le A, Park J, Johnson-Mallard V, Elias M, Moscoso M, Goodman M, Kip K. (2017) A Randomized Controlled Trial of the Effects of Mindfulness-Based Stress Reduction (MBSR[BC]) on Levels of Inflammatory Biomarkers Among Recovering Breast Cancer Survivors. *Biol Res Nurs* 19(4):456-464. PMID: 28460534 PMC ID: PMC5942506
7. Husain K, Centeno B, Coppola D, Trevino J, Sebti S, Malafa M. (2017) δ -Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. *Oncotarget* 8(19):31554-31567. PMID: 28404939 PMC ID: PMC5458229
8. Wingard J, Wood W, Martens M, Le-Rademacher J, Logan B, Knight J, Jacobsen P, Jim H, Majhail N, Syrjala K, Rizzo J, Lee S. (2017) Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). *Biol. Blood Marrow Transplant.* 23(1):161-164. PMID: 27742574 PMC ID: PMC5182134
9. Extermann M, Leeuwenburgh C, Samiiian L, Sehovic M, Xu J, Cubitt C, Jacobsen P, Pahor M, Grobmyer S, Manini. (2017) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. *J Geriatr Oncol* 8(1):69-75. PMID: 27743848 PMC ID: PMC5299045
10. Reich R, Lengacher C, Alinat C, Kip K, Paterson C, Ramesar S, Han H, Ismail-Khan R, Johnson-Mallard V, Moscoso M, Budhrani-Shani P, Shivers S, Cox C, Goodman M, Park J. (2017) Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. *J Pain Symptom Manage* 53(1):85-95. PMID: 27720794

UF Health-Sylvester-Moffitt

1. Permuth J, Chen D, Yoder S, Li J, Smith A, Choi J, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno B, Klapman J, Hodul P, Karreth F, Trevino J, Merchant N, Magliocco A, Malafa M, Gillies R. (2017) Linc-ing

Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Sci Rep* 7(1):10484. PMID: 28874676 PMC ID: PMC5585319

2. Liu H, Ahn K, Hu Z, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald M, Sabloff M, Olsson R, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks D, Copelan E, Gergis U. (2017) Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biol. Blood Marrow Transplant.* 23(5):767-775. PMID: 28115276 PMC ID: PMC5590102
3. Permuth J, Choi J, Chen D, Jiang K, DeNicola G, Li J, Coppola D, Centeno B, Magliocco A, Balagurunathan Y, Merchant N, Trevino J, Jeong D. (2017) A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? *Cancer Biol Med* 14(1):66-73. PMID: 28443205 PMC ID: PMC5365183

Sylvester Collaborative Publications

	# Collaborative Publications Sylvester-UF Health	# Collaborative Publications Sylvester-Moffitt	# Collaborative Publications Sylvester-UF Health-Moffitt	Total Publications by Year
2019	5	16	6	27
2018	4	10	0	14
2017	4	10	3	17
TOTALS	13	36	9	58

2019

Sylvester-UF Health

1. Luo H, Zhu G, Xu J, Lai Q, Yan B, Guo Y, Fung T, Zeisig B, Cui Y, Zha J, Cogle C, Wang F, Xu B, Yang F, Li W, So C, Qiu Y, Xu M, Huang S. (2019) HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. *Cancer Cell* 36(6):645-659.e8. PMID: 31786140 PMC ID: PMC6917035
2. Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang C, Ali A, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. (2019) A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. *Breast* 49():141-148. PM ID: 31805500
3. Carrier F, Liao Y, Mendenhall N, Guerrieri P, Todor D, Ahmad A, Dominello M, Joiner M, Burmeister J. (2019) Three Discipline Collaborative Radiation Therapy (3DCRT) Special Debate: I would treat prostate cancer with proton therapy. *J Appl Clin Med Phys* 20(7):7-14. PMID: 31166085 PMC ID: PMC6612688
4. Sundermann A, Clancy C, Pasculle A, Liu G, Cumbie R, Driscoll E, Ayres A, Donahue L, Pergam S, Abbo L, Andes D, Chandrasekar P, Galdys A, Hanson K, Marr K, Mayer J, Mehta S, Morris M, Perfect J, Revankar S, Smith B, Swaminathan S, Thompson G, Varghese M, Vazquez J. (2019) How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. *Clin. Infect. Dis.* 68(5):850-853. PMID: 30299481
5. Asfar T, Ben Taleb Z, Osibogun O, Ruano-Herrera E, Sierra D, Ward K, Salloum R, Maziak W. (2019) How Do Waterpipe Smoking Establishments Attract Smokers? Implications for Policy. *Subst Use Misuse* 54(4):560-571. PMID: 30430905 PMC ID: PMC6443473

Sylvester-Moffitt

1. Ustun C, Young JAH, Papanicolaou GA, Kim S, Ahn KW, Chen M, Abdel-Azim H, Aljurf M, Beitinjaneh A, Brown V, Cerny J, Chhabra S, Kharfan-Dabaja MA, Dahi PB, Daly A, Dandoy CE, Dvorak CC, Freytes CO, Hashmi S, Lazarus H, Ljungman P, Nishihori T, Page K, Pingali SRK, Saad A, Savani BN, Weisdorf D, Williams K, Wirk B, Auletta JJ, Lindemans CA, Komanduri K, Riches M. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*. 2019;54(8):1254-65. doi: 10.1038/s41409-018-0401-4. PubMed PMID: WOS:000479117700010.
2. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients \geq 65 years with non-Hodgkin lymphoma: a time-trend analysis. *Blood Cancer Journal*. 2019;9. doi: 10.1038/s41408-019-0261-1. PubMed PMID: WOS:000502873800001.
3. Rudra S, Jiang NM, Rosenberg SA, Olsen JR, Roach MC, Wan LP, Portelance L, Mellon EA, Bruynzeel A, Lagerwaard F, Bassetti MF, Parikh PJ, Lee PP. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. *Cancer Medicine*. 2019;8(5):2123-32. doi: 10.1002/cam4.2100. PubMed PMID: WOS:000469272500017.
4. Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang RX, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Razak ARA, Wilky B, Iyengar M, Trivedi T, Van Winkle E, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. *Journal for Immunotherapy of Cancer*. 2019;7(1). doi: 10.1186/s40425-019-0762-2. PubMed PMID: WOS:000493082200002.
5. Permuth JB, Daly AC, Jeong D, Choi JW, Cameron ME, Chen DT, Teer JK, Barnett TE, Li JN, Powers BD, Kumar NB, George TJ, Ali KN, Huynh T, Vyas S, Gwede CK, Simmons VN, Hodul PJ, Carballido EM, Judge AR, Fleming JB, Merchant N, Trevino JG, Florida Pancreas C. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. *Cancer Medicine*. 2019;8(6):3314-24. doi: 10.1002/cam4.2180. PubMed PMID: WOS:000474292100059.
6. Palta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N, Parekh A, Patton C, Pepek JM, Salama JK, Tuli R, Koong AC. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*. 2019;9(5):322-32. doi: 10.1016/j.prro.2019.06.016. PubMed PMID: WOS:000483978300016.
7. Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoefflich KP, Shi HL, Wolf BB, Kang YK. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. *Cancer Discovery*. 2019;9(12):1696-707. doi: 10.1158/2159-8290.Cd-19-0555. PubMed PMID: WOS:000500270700023.
8. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorrow ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobeks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow

Transplant Research Report. *Clinical Cancer Research*. 2019;25(16):5143-55. doi: 10.1158/1078-0432.Ccr-18-3988. PubMed PMID: WOS:000481912400030.

9. Kasting ML, Giuliano AR, Reich RR, Roetzheim RG, Duong LM, Thomas E, Nelson DR, Shenkman E, Vadaparampil ST. Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. *Cancer Epidemiology*. 2019;60:112-20. doi: 10.1016/j.canep.2019.03.007. PubMed PMID: WOS:000468123300017.
10. Goncalves J, Emmons MF, Faiao-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM. Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell & Melanoma Research*. 2019. doi: 10.1111/pcmr.12849. PubMed PMID: WOS:000500949800001.
11. Falahat R, Perez-Villarroel P, Mailloux AW, Zhu GY, Pilon-Thomas S, Barber GN, Mule JJ. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. *Cancer Immunology Research*. 2019;7(11):1837-48. doi: 10.1158/2326-6066.Cir-19-0229. PubMed PMID: WOS:000494359300010.
12. Faiao-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM. HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clinical Cancer Research*. 2019;25(18):5686-701. doi: 10.1158/1078-0432.Ccr-18-3382. PubMed PMID: WOS:000487704400027.
13. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. *Journal of Hematology & Oncology*. 2019;12. doi: 10.1186/s13045-018-0696-z. PubMed PMID: WOS:000455459800001.
14. Byrne MM, Thurer RJ, Studts JL. Individual decision making about lung cancer screening: A conjoint analysis of perspectives among a high-risk national sample. *Cancer Medicine*. 2019;8(12):5779-86. doi: 10.1002/cam4.2445. PubMed PMID: WOS:000479310600001.
15. Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management Across Settings An ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings. *Clinical Journal of Oncology Nursing*. 2019;23(2):27-34. doi: 10.1188/19.Cjon.S1.27-34. PubMed PMID: WOS:000461477600005.
16. Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahi PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk BM, Auletta J, Lindemans C, Riches M. Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. *Bone Marrow Transplantation*. 2019;54(8):1354-60. doi: 10.1038/s41409-019-0457-9. PubMed PMID: WOS:000479117700022.

Sylvester-Moffitt-UF Health

1. Gonçalves J, Emmons M, Faião-Flores F, Aplin A, Harbour J, Licht J, Wink M, Smalley K. (2019) Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell Melanoma Res*. PMID: 31758842
2. Zhao N, Peacock S, Lo C, Heidman L, Rice M, Fahrenholtz C, Greene A, Magani F, Copello V, Martinez M, Zhang Y, Daaka Y, Lynch C, Burnstein K. (2019) Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. *Sci Transl Med* 11(498). PMID: 31243151

3. Faião-Flores F, Emmons M, Durante M, Kinose F, Saha B, Fang B, Koomen J, Chellappan S, Maria-Engler S, Rix U, Licht J, Harbour J, Smalley K. (2019) HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clin. Cancer Res.* PMID: 31227503
4. Kasting M, Giuliano A, Reich R, Roetzheim R, Duong L, Thomas E, Nelson D, Shenkman E, Vadaparampil S. (2019) Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. *Cancer Epidemiol* (60):112-120. PMID: 30953971 PMC ID: PMC6527446
5. Permutth J, Clark Daly A, Jeong D, Choi J, Cameron M, Chen D, Teer J, Barnett T, Li J, Powers B, Kumar N, George T, Ali K, Huynh T, Vyas S, Gwede C, Simmons V, Hodul P, Carballido E, Judge A, Fleming J, Merchant N, Trevino J. (2019) Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. *Cancer Med* 8(6):3314-3324. PMID: 31074202 PMC ID: PMC6558500
6. Seay J, Hicks A, Markham M, Schlumbrecht M, Bowman M, Woodard J, Kollfrath A, Diego D, Quinn G, Schabath M. (2019) Developing a web-based LGBT cultural competency training for oncologists: The COLORS training. *Patient Educ Couns.* PMID: 30642714

2018

Sylvester-UF Health

1. Tyner J, Tognon C, Bottomly D, Wilmot B, Kurtz S, Savage S, Long N, Schultz A, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang B, Coblenz C, d'Almeida A, Cook R, Danilov A, Dao K, Degnin M. (2018) Functional genomic landscape of acute myeloid leukaemia. *Nature* 562(7728):526-531. PMID: 30333627 PMC ID: PMC6280667
2. Luo H, Wang F, Zha J, Li H, Yan B, Du Q, Yang F, Sobh A, Vulpe C, Drusbosky L, Cogle C, Chepelev I, Xu B, Nimer S, Licht J, Qiu Y, Chen B, Xu M, Huang S. (2018) CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. *Blood* 132(8):837-848. PMID: 29760161 PMC ID: PMC6107877
3. Barredo J, Hastings C, Lu X, Devidas M, Chen Y, Armstrong D, Winick N, Wood B, Yanofsky R, Loh M, Gastier-Foster J, Jorstad D, Marcus R, Ritchey K, Carrol W, Hunger S. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. *Pediatr Blood Cancer* 65(5):e26928. PMID: 29286562 PMC ID: PMC6136835
4. Swords R, Azzam D, Al-Ali H, Lohse I, Volmar C, Watts J, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers S, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle C, Wahlestedt C. (2018) Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. *Leuk. Res.* 64():34-41. PMID: 29175379 PMC ID: PMC5756519

Sylvester-Moffitt

1. Weinfurter RJ, Niell B, Mekhail Y, Aguila E, Kamat L. Specialized Second Opinion Interpretations of Breast Imaging: Impact on Additional Workup and Management. *Clinical Breast Cancer.* 2018;18(5):E1031-E6. doi: 10.1016/j.clbc.2018.03.009. PubMed PMID: WOS:000445702400040.
2. Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kamnietzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. *Journal of Clinical Oncology.* 2018;36(9):859-+. doi: 10.1200/jco.2017.75.5207. PubMed PMID: WOS:000429062700005.

3. Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay. *Jama Oncology*. 2018;4(1). doi: 10.1001/jamaoncol.2017.3470. PubMed PMID: WOS:000422795300001.
4. Trucco M, Barredo JC, Goldberg J, Leclerc GM, Hale GA, Gill J, Setty B, Smith T, Lush R, Lee JK, Reed DR. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin. *Pediatric Blood & Cancer*. 2018;65(9). doi: 10.1002/pbc.27224. PubMed PMID: WOS:000439863700010.
5. Peterson SL, Husnain M, Pollack T, Pimentel A, Loaiza-Bonilla A, Westendorf-Overley C, Ratermann K, Anthony L, Desimone P, Goel G, Kudrimoti M, Dineen S, Tzeng CWD, Hosein PJ. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. *Anticancer Research*. 2018;38(7):4035-9. doi: 10.21873/anticancer.12692. PubMed PMID: WOS:000449943500031.
6. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical Lung Cancer*. 2018;19(3):280-+. doi: 10.1016/j.clcc.2017.12.007. PubMed PMID: WOS:000430510300019.
7. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirter R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. *Neuro-Oncology*. 2018;20(5):674-86. doi: 10.1093/neuonc/nox208. PubMed PMID: WOS:000430161300012.
8. Lee MS, Tyson DM, Gonzalez BD, Small BJ, Lechner SC, Antoni MH, Vinard A, Krause M, Meade C, Jacobsen PB. Anxiety and depression in Spanish-speaking Latina cancer patients prior to starting chemotherapy. *Psycho-Oncology*. 2018;27(1):333-8. doi: 10.1002/pon.4462. PubMed PMID: WOS:000422995000044.
9. Konno H, Yamauchi S, Berglund A, Putney RM, Mule JJ, Barber GN. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. *Oncogene*. 2018;37(15):2037-51. doi: 10.1038/s41388-017-0120-0. PubMed PMID: WOS:000429899400007.
10. Hoogland AI, Lechner SC, Gonzalez BD, Small BJ, Tyson DM, Asvat Y, Barata A, Gomez MF, Rodriguez Y, Jim HSL, Antoni MH, Jacobsen PB, Meade CD. Efficacy of a Spanish-Language Self-Administered Stress Management Training intervention for Latinas undergoing chemotherapy. *Psycho-Oncology*. 2018;27(4):1305-11. doi: 10.1002/pon.4673. PubMed PMID: WOS:000430230400028.

2017

Sylvester-UF Health

1. Diaby V, Ali A, Williams K, Ezendu K, Soto-Perez-de-Celis E, Chavarri-Guerra Y, de Lima Lopes G. (2017) Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. *Breast Cancer Res. Treat.* 166(3):951-963. PMID: 28840424
2. Hardy K, Embry L, Kairalla J, Helian S, Devidas M, Armstrong D, Hunger S, Carroll W, Larsen E, Raetz E, Loh M, Yang W, Relling M, Noll R, Winick N. (2017) Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and

Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. *J. Clin. Oncol.* 35(23):2700-2707. PMID: 28671857 PMC ID: PMC5549456

3. Gea-Banacloche J, Komanduri K, Carpenter P, Paczesny S, Sarantopoulos S, Young J, El Kassir N, Le R, Schultz K, Griffith L, Savani B, Wingard J. (2017) National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. *Biol. Blood Marrow Transplant.* 23(6):870-881. PMID: 27751936 PMC ID: PMC5392182
4. Pan F, Wingo T, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega J, Wang J, Nazha A, Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips B, Huang S, Wang J, He C, Li G, Radivoyevitch T, Aifantis I, Maciejewski J. (2017) Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. *Nat Commun* 8():15102. PMID: 28440315 PMC ID: PMC5414116

Sylvester-Moffitt

1. Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao JJ, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. *Neuro-Oncology.* 2017;19(10):1380-90. doi: 10.1093/neuonc/nox086. PubMed PMID: WOS:000410404200018.
2. Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E, Berz D. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. *Lung Cancer.* 2017;108:22-8. doi: 10.1016/j.lungcan.2017.02.010. PubMed PMID: WOS:000405261300005.
3. Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. *Lancet Oncology.* 2017;18(2):202-11. doi: 10.1016/s1470-2045(16)30648-9. PubMed PMID: WOS:000396343000046.
4. Saeed NA, Mellon EA, Meredith KL, Hoffe SE, Shridhar R, Frakes J, Fontaine JP, Pimiento JM, Kothari N, Almhanna K. Adjuvant chemotherapy and outcomes in esophageal carcinoma. *Journal of Gastrointestinal Oncology.* 2017;8(5):816-24. doi: 10.21037/jgo.2017.07.10. PubMed PMID: WOS:000413224600009.
5. Permuth JB, Choi JW, Chen DT, Jiang K, DeNicola G, Li JN, Coppola D, Centeno BA, Magliocco A, Balagurunathan Y, Merchant N, Trevino JG, Jeong D, Florida Pancreas C. A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? *Cancer Biology & Medicine.* 2017;14(1):66-73. doi: 10.20892/j.issn.2095-3941.2017.0006. PubMed PMID: WOS:000401102700007.
6. Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W, Ctr Int Blood Marrow Transplant R, Res Collaboration Natl Marrow D. Cytogenetic Risk Determines Outcomes After Allogeneic Transplantation in Older Patients With Acute Myeloid Leukemia in Their Second Complete Remission: A Center for International Blood and Marrow Transplant Research Cohort Analysis. *Cancer.* 2017;123(11):2035-42. doi: 10.1002/cncr.30567. PubMed PMID: WOS:000401841700022.
7. Mellon EA, Orman A, Joya LE, Montejó ME, Laronga C, Hoover SJ, Lee MC, Khakpour N, Kubal PF, Diaz R. Frequency of whole breast radiation therapy after intraoperative radiation therapy due to criteria identified by lumpectomy. *Brachytherapy.* 2017;16(1):174-80. doi: 10.1016/j.brachy.2016.09.012. PubMed PMID: WOS:000392793900019.

8. Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. *Acta Oncologica*. 2017;56(3):391-7. doi: 10.1080/0284186x.2016.1256497. PubMed PMID: WOS:000396774900003.
9. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellstrom-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, del Canizo C, Greenberg PL, Shammo JM, Skikne B, Yu XJ, List AF. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). *Journal of Hematology & Oncology*. 2017;10. doi: 10.1186/s13045-017-0491-2. PubMed PMID: WOS:000404058800001.
10. Chow LWC, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CYC, Loo WTY, Gluck S, Toi M. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. *Asia-Pacific Journal of Clinical Oncology*. 2017;13(6):372-8. doi: 10.1111/ajco.12682. PubMed PMID: WOS:000427541000006.

Sylvester-Moffitt-UF Health

1. Permuth J, Chen D, Yoder S, Li J, Smith A, Choi J, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno B, Klapman J, Hodul P, Karreth F, Trevino J, Merchant N, Magliocco A, Malafa M, Gillies R. (2017) Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Sci Rep* 7(1):10484. PMID: 28874676 PMC ID: PMC5585319
2. Liu H, Ahn K, Hu Z, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald M, Sabloff M, Olsson R, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks D, Copelan E, Gergis U. (2017) Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biol. Blood Marrow Transplant*. 23(5):767-775. PMID: 28115276 PMC ID: PMC5590102
3. Permuth J, Choi J, Chen D, Jiang K, DeNicola G, Li J, Coppola D, Centeno B, Magliocco A, Balagurunathan Y, Merchant N, Trevino J, Jeong D. (2017) A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? *Cancer Biol Med* 14(1):66-73. PMID: 28443205 PMC ID: PMC5365183

Attachment 2:

Agendas for the following completed meetings and retreats are provided in the following pages.

Event	Date	Location	Organizing Center
2017 FACCA Annual Research Retreat	April 18-19, 2017	Lake Nona, FL	UF Health
Microbiome Think Tank Retreat	January 22-23, 2018	Gainesville, FL	UF Health
2018 FACCA Annual Research Retreat	May 2-3, 2018	Tampa, FL	Moffitt
Disparities Think Tank Retreat	May 3, 2018	Tampa, FL	Sylvester
2019 FACCA Annual Research Retreat	June 13-14, 2019	Miami, FL	Sylvester



Florida Academic Cancer Center Alliance (FACCA) Research Retreat II
UF Research & Academic Center at Lake Nona – April 18-19, 2017
6550 Sanger Road, Orlando, FL 32827

TUESDAY, APRIL 18, 2017

- 10:30 am-12:00 pm** **Retreat Registration** (*Atrium*)
- Poster Set-up**
- 12:00 pm-12:45 pm** **Lunch** (*Rm 131/132*)
- 12:45 pm-1:00 pm** **Opening Remarks** (*Auditorium*)
Jonathan Licht, MD [UF]
John Cleveland, PhD [Moffitt]
Stephen Nimer, MD [SCCC]
- 1:00 pm-2:00 pm** **Topic 1: Epigenetics**
Discussion Session w/faculty from each center
Maria Figueroa, MD [SCCC]
Jonathan Licht, MD [UF]
Florian Karreth, PhD [Moffitt]
- 2:00 pm-2:10 pm** **Discussion**
- 2:10 pm-2:30 pm** FACCA Pilot Project
The role of HoxB1nc INCR in NPM1 mutation-mediated pathogens of myeloid malignancies
Suming Huang, PhD [UF]
Mingjiang Xu, MD, PhD [SCCC]
- 2:30 pm-2:50 pm** FACCA Pilot Project
Defining and targeting the epigenetic landscape of uveal melanoma
Keiran Smalley, PhD [Moffitt]
Jonathan Licht, MD [UF]
William Harbour, MD [SCCC]
- 2:50 pm-3:00 pm** **Discussion**
- 3:00 pm-3:20 pm** **Break**
- 3:20 pm-4:20 pm** **Topic 2: Health Outcomes**
Discussion Session w/faculty from each center
Susan Vadaparampil, PhD [Moffitt]
Erin N. Kobetz, PhD, MPH [SCCC]
Yi Guo, PhD [UF]
- 4:20 pm-4:30 pm** **Discussion**

TUESDAY, APRIL 18, 2017 *continued*

4:30 pm-4:50 pm FACCA Pilot Project
The effect of Immigration on the development of breast cancer in women of African descent
Susan Vadaparampil, PhD, MPH [Moffitt]
Vincent DeGennaro, MD, MPH [UF]
Judith Hurley, MD [SCCC]
Sophia George, PhD [SCCC]

4:50 pm-5:00 pm **Discussion**

5:00 pm-6:30 pm **Poster Session/Cocktails** (*Atrium*)

5:45 pm-6:30 pm **Poster Session** (*continued*)

Topic Tables

Topic 1: High-performance Bioinformatics for Cancer Research

Facilitators: **Steven Eschrich, PhD** [Moffitt] & **Alberto Riva, PhD** [UF]

Topic 2: Application of NGS in Epigenetics and noncoding RNA Research

Facilitators: **Rolf Renne, PhD** [UF] & **Michael Kladde, PhD** [UF]

Topic 3: Gnotobiotic Technology to Study Microbiota Role in Preclinical Cancer Model

Facilitators: **Christian Jobin, PhD** [UF] & **Conor Lynch, PhD** [Moffitt]

Retrieve Posters

6:30 pm **Seated Dinner** (*Rm 131/132*)

FACCA Pilot Project

Gut microflora and estrogens: a new paradigm for breast cancer risk reduction

Kathleen Egan, ScD [Moffitt]

Lusine Yaghjyan, MD, MPH, PhD [UF]

FACCA Pilot Project

Role of AVPR1a in metastatic castration resistant prostate cancer

Conor Lynch, PhD [Moffitt]

Yehia Daaka, PhD [UF]

Kerry Burnstein, PhD [SCCC]

FACCA Pilot Project

Modeling the patterns of breast cancer early metastases

Walter O'Dell, PhD [UF]

Christine Takita, MD, MBA [SCCC]

FACCA Pilot Project

The Florida pancreas cancer collaboration: a partnership dedicated to the prevention and early detection of pancreatic cancer

Jenny Permuth, PhD, MS [Moffitt]

Mokenge Malafa, MD [Moffitt]

Jose Trevino, MD [UF]

Nipun Merchant, MD [SCCC]

WEDNESDAY, APRIL 19, 2017

- 7:15 am** **Breakfast** (*Rm 131/132*)
- 7:45 am-8:00 am** **Opening Remarks** (*Auditorium*)
John Cleveland, PhD [Moffitt]
Stephen Nimer, MD [SCCC]
Jonathan Licht, MD [UF]
- 8:00 am-9:00 am** **Topic 3: Viral Oncology**
Discussion Session w/faculty from each center
Scott Tibbetts, PhD [UF]
Peter Forsyth, MD [Moffitt]
Noriyuki Kasahara, MD, PhD [SCCC]
- 9:00 am-9:10 am** **Discussion**
- 9:10 am-9:30 am** FACCA Pilot Project
Oncogenic role of KSHV micro RNAs in cell and animal models of Kaposi's sarcoma
Enrique Mesri, PhD [SCCC]
Rolf Renne, PhD [UF]
- 9:30 am-9:40 am** **Discussion**
- 9:40 am-10:00 am** **Break**
- 10:00 am-11:00 am** **Topic 4: Drug Development**
Discussion Session w/faculty from each center
Shaun Brothers, PhD [SCCC]
Chengguo (Chris) Xing, PhD [UF]
Haitao (Mark) Ji, PhD [Moffitt]
- 11:00 am-11:10 am** **Discussion**
- 11:10 am-11:30 am** FACCA Pilot Project
RAGE signaling through the inflammasome: novel combined inflammatory therapeutic targets in cancer
Alan List, MD [Moffitt]
Sheng Wei, MD [Moffitt]
Barry Hudson, PhD [SCCC]
Marc Lippman, MD [SCCC]
- 11:30 am-11:50 am** FACCA Pilot Project
Targeting mitotic functions of TBK1 and Cdk2 to combat cancer
Srikumar Chellappan, PhD [Moffitt]
Brian Law, PhD [UF]
- 11:50 am-12:00 pm** **Discussion**
- 12:00 pm-12:15 pm** **Closing Remarks**
Stephen Nimer, MD [SCCC]
John Cleveland, PhD [Moffitt]
Jonathan Licht, MD [UF]
- 12:15 pm** **Adjourn**

***Florida Academic Cancer Center Alliance (FACCA)
Microbiome Research Retreat
UF Health Cancer Center***

Attendees:

UF Health Cancer Center



Christian Jobin, PhD



Hendrik Luesch, PhD



Raad Gharaibeh, PhD

Moffitt Cancer Center



Jose Conejo-Garcia,
MD, PhD



Christine Pierce, PhD,
MPH



Kathleen Egan, ScD



Lowell Smith

UM Sylvester Comprehensive Cancer Center



Maria Abreu, MD



Sabita Roy, PhD



Cynthia Thiry, MS

Monday, January 22, 2018

- 5:00PM Shuttle will pick guests up from the UF Hilton and transport to the restaurant
- 5:15PM Meet and Greet at Leonardo's 704 Private Dining Room
- 6:00PM Dinner at Leonardo's 704 Private Dining Room at 706 West University Ave., Gainesville, Florida
- 7:15PM Shuttle will transport guests back to the UF Hilton

Tuesday, January 23, 2018

7:30AM Shuttle pick up from the UF Hilton to the UF Health Cancer Center

8:00AM Breakfast

8:30AM Welcome and Introduction – Dr. Jonathan Licht

8:45AM Scientific overview of research sites
(Expertise, technology, clinical samples, population, etc)

a) UF

b) Moffitt

c) Miami

9:45AM Break

10:00AM Brainstorming potential projects

11:30PM Lunch

12:00PM Prioritize project and strategic development

1:45PM Summary and future steps

2:00PM Adjourn

Shuttle Service will pick up Miami attendees from the UF Health Cancer Center and transport to the Gainesville Regional Airport

WEDNESDAY, May 2, 2018

✓ = Presenter/Moderator

10:00 a.m. - 12:00 p.m.

Registration/Check-in

10:00A – 12:00P Concurrent Sessions:

- *Directors Meeting: Center Directors & ADs of Administration Only*
- *Microbiome Think Tank Taskforce Follow-up Meeting*

12:00 p.m. – 12:45 p.m.

Welcome & Lunch

Tom Sellers, PhD (MCC)✓

Special Guests:

Nicole de Lara Puente, CEO-Live Live Like Bella®, Childhood Cancer Foundation Mark
K. Delegal, Esq - Holland & Knight, Tallahassee, FL

12:45 p.m. – 1:30 p.m.

Think Tanks:

Introduction to Think Tank Concept

Jonathan D. Licht, MD (UF)✓

January Microbiome Think Tank Update

Christine Pierce, PhD (MCC)✓

Jose Conejo-Garcia, MD, PhD(MCC)✓

Kathleen Egan (MCC)

Maria Abreu (UM) Sabita

Roy, PhD (UM)

Raad Gharaibeh, PhD (UF)

Christian Jobin, PhD (UF)

Hendrik Luesch, PhD (UF)

1:30 p.m. – 2:15 p.m.

Where are we now? Year 1 - 2015 FACCA Project Updates

(5 min. presentation, 5 min. Q&A)

Gut Microflora and Estrogens

Lusine Yaghjian, MD, MPH, PhD (UF) ✓

Kathleen Egan, ScD (MCC)

Role of GPCR

Kerry Burnstein, PhD (UM)✓

Conor Lynch, PhD (MCC) Yehia

Daaka, PhD (UF)

Modeling Patterns of Breast Cancer Early Metastases

Walter O'Dell, PhD (UF)✓

Christine Takita, MD (UM)

Where are we now? Year 1/3 – 2015/2017 Project Update (Competing Renewal) (7.5 min. presentation, 7.5 min. Q&A)

Florida Pancreas Cancer Collaborative

Jenny Permeth, PhD (MCC)✓ Mokenge

Malafa, MD (MCC)

Jose Trevino, MD (UF) Nipun

Merchant, MD (UM)

2:15 p.m. – 3:15 p.m.

Table Topics 1 – 4

1. Cancer Moonshot Topic:

Mine past patient data to predict future patient outcomes

Moderator: Jiang Bian, PhD (UF)

2. NCI Provocative Question:

What are the predictive biomarkers for the onset of immune-related adverse events associated with checkpoint inhibition and are they related to markers for efficacy?

Moderator: Elias Sayour, MD, PhD (UF)

3. Medical Marijuana Research:

Moderators: Nagi Kumar, PhD (MCC) and Sabita Roy, PhD (UM)

4. Pediatric Cancer Research Collaborations:

Moderator: Jonathan D. Licht, MD (UF)

Special Guest: Nicole de Lara Puente, CEO Live Like Bella® Childhood Cancer Foundation

3:15 p.m. - 3:30 p.m.

Break

3:30 p.m. – 4:30 p.m.

Where are we now? Year 3 – 2017 Project Updates

(7.5 min. presentation, 7.5 min. Q&A)

Virotherapy combination strategy for glioblastoma

Peter Forsyth, MD (MCC) ✓

Noriyuki Kasahara, MD, PhD (UM)

Florida increases rates of screening and treatment of hepatitis C virus (FIRST HCV)

Anna Giuliano, PhD (MCC) ✓

Elizabeth Shenkman, PhD (UF)

Patricia Jones, MD (UM)

Developing provider-focused LGBT communication skill building for Oncologists

Matthew Schabath, PhD (MCC) ✓

Merry Jennifer Markham, MD (UF)

Amanda Hicks, PhD (UF)

Julia Seay, PhD (UM)

Matthew Schlumbrecht, MD, MPH (UM)

Gwen Quinn, PhD (Formerly MCC/Now at NYU)

Preventative vaccination against neoantigens in MRD and premalignant settings

Elias Sayour, MD, PhD (UF) ✓

Eli Gilboa, PhD (UM)

Florida Academic Cancer Center Alliance

Moffitt Cancer Center
Sylvester Comprehensive Cancer Center
University of Florida Health Cancer Center

2018 Annual Retreat

May 2–3, 2018
AC Hotel
4020 Boy Scout Boulevard Tampa, FL 33607
(813) 350-4020

- 4:30 p.m. – 5:30 p.m.** **Focused Session 1**
Ongoing Basic Science and Clinical Collaborations between Academic Cancer Centers. What works and what are the obstacles?
 Frederic Kaye, MD (UF)✓
 William Harbour, MD (UM)✓
- 5:30 p.m. – 6:00 p.m.** **Break/Free Time**
- 6:00 p.m.** **Meet in AC Hotel Bar for walk to Cooper’s Hawk**
- 6:00 p.m. – 7:00 p.m.** **Cocktail Reception**
- 7:00 p.m. – 9:00 p.m.** **Dinner**

See next page for Day 2

THURSDAY, May 3, 2018

7:45 a.m. – 8:15 a.m. **Enjoy the AC Hotel Buffet Breakfast**

8:15 a.m. – 9:15 a.m. **Where are we now? Year 2 – 2016 Project Updates**
(5 min. presentation, 5 min. Q&A)

Targeting mitotic functions of TBK1 and Cdk2 to combat cancer

Srikumar Chellappan, PhD (MCC)✓
Brian Law, PhD (UF)

The role of HoxB1 and INCRA in NPM1 mutation-mediated pathogenesis of myeloid malignancies

Mingjang Xu, MD, PhD (UM)✓
Suming Huang, PhD (Formerly UF)

Oncogenic role of KSHV micro RNAs in cell and animal models of Kaposi's sarcoma

Rolf Renne, PhD (UF)✓
Enrique Mesri, PhD (UM)

RAGE signaling through the inflammasome: novel combined inflammatory therapeutic targets in cancer

Barry Hudson, PhD (UM)✓
Marc Lippman, MD (UM)
Alan List, MD (MCC)
Sheng Wei, PhD (MCC)

Defining and targeting the aberrant chromatin function in uveal melanoma

William Harbour, MD (UM)✓
Keiran Smalley, PhD (MCC)
Jonathan D. Licht, MD (UF)

The effect of Immigration on the development of breast cancer in women of African descent

Sophia George, PhD (UM)✓
Judith Hurley, MD (UM)
Vincent DeGennaro, Jr. MD, MPH (UF)
Susan Vadaparampil, PhD (MCC)

9:15 a.m. – 10:15 a.m.

Table Topics 5 – 7

5. NCI Provocative Question:

Do genetic interactions between germline variations and somatic mutations contribute to differences in tumor evolution or response to therapy?

Moderator: John Cleveland, PhD (MCC)

6. NCI Provocative Question:

Through what mechanisms do diet and nutritional interventions affect the response to cancer treatment?

Moderator: David Janicke, PhD, ABPP (UF)

7. Cancer Moonshot Topic:

Develop ways to overcome cancer's resistance to therapy

Moderator: Jose Conejo-Garcia, MD, PhD (MCC)

10:15 a.m. – 10:45 a.m.

Shared Resources - Unique Cores

UM: Behavioral and Community-Based Research Shared Resource (BCSR)

Olveen Carrasquillo, MD, MPH

MCC: Cell Therapies

Cheryl Cox, MT (ASCP)

Ed Seijo, MS

UF: Drug Discovery

Ranjala Ratnayake, PhD

10:45 a.m. – 11:00 a.m.

Break

11:00 a.m. – 12:00 p.m.

Focused Session 2

Catchment Area – clinical trials, population needs, special populations, targeting research

Elizabeth Shenkman, PhD (UF)

Erin Kobetz, PhD, MPH (UM)

Susan Vadaparampil, PhD (MCC)

12:00 p.m.

Closing Remarks

Tom Sellers, PhD (MCC)

12:05 p.m.

Adjourn - Grab and go lunch!

12:30 p.m.

Disparities Think Tank Meeting

(See next page for Think Tank agenda)

THURSDAY, May 3, 2018

Disparities Think Tank Meeting

University of Miami – Lead Site

Erin Kobetz, PhD, MPH
Olveen Carrasquillo, MD, MPH
Barbara Vance, PhD, CRA
Cynthia Thiry, MS

University of Florida

Elizabeth Shenkman, PhD
Jiang Bian, PhD
Deepa Ranka, PhD
Robert Houlihan, PhD
Diana Wilkie, PHD, RN, FAAN
Folakemi Odedina, PhD
Wendy Malorzo
Jamie Ramos

Moffitt Cancer Center

Susan Vadaparampil, PhD
Stephanie Schmit, PhD
Clement Gwede, PhD, MPH, RN, FAAN
Brian C. Springer, MHA
Lowell Smith, MA

- | | |
|--------------------------------|--|
| 12:30 p.m. – 12:45 p.m. | Lunch, Welcome & Introductions
Erin Kobetz, PhD, MPH (UM) |
| 12:45 p.m. – 1:45 p.m. | Scientific Overview of Research Sites (expertise, technology, population, etc.) |
| 1:45 p.m. – 3:45 p.m. | Brainstorming Potential Projects |
| 3:45 p.m. - 5:15 p.m. | Prioritize Project & Strategic Development |
| 5:15 p.m. – 5:30 p.m. | Summary & Future Steps |

Thursday, June 13, 2019 (All sessions will take place on the 5th Floor)

✓ = Moderator

- 10:00 a.m. - 12:00 p.m.** **Registration/Check-in** (Foyer outside Salon EFG)
10:00A – 12:00P Concurrent Sessions (New York Room)
• *Directors Meeting: Center Directors & ADs of Administration Only*
- 12:00 p.m. – 12:05 p.m.** **Welcome & Lunch** (Salon EF)
Stephen D. Nimer, MD (Sylvester) ✓
- 12:05 p.m. – 12:50 p.m.** **FACCA ROI and Statewide Areas of Concern and How We Can Address Together as State Cancer Control Plan** (Salon EF)
(15 minute discussion)
Tom Sellers, PhD, MPH (Moffitt)
Jonathan D. Licht, MD (UF)
Stephen D. Nimer, MD (Sylvester)
- 12:50 p.m. – 1:35 p.m.** **Think Tank Update** (Salon EF)
(20 minute discussion)
Microbiome
Christine M. Pierce, PhD, MPH (Moffitt) ✓
Raad Gharaibeh, PhD (UF)
Sabita Roy, PhD (Sylvester)
- 1:35 p.m. – 2:35 p.m.** **Breakout Sessions 1 – 2**
- 1. Screening For New Vulnerabilities** (Salon EF)
 Michael B. Mann, PhD (Moffitt) ✓
 Stephan Schurer, PhD (Sylvester)
 Richard Bennett, PhD (UF)
- 2. Site Disease Focused – Pancreas** (Salon G)
 Nipun B. Merchant, MD (Sylvester) ✓
 Patrick Underwood, MD (UF)
 Jenny B. Permeth, PhD (Moffitt)
- 2:35 p.m. – 2:50 p.m.** **Break**
- 2:50 p.m. – 3:40 p.m.** **Focused Session 1 – Infectious Disease** (Salon EF)
(20 minute discussion)
HIV and Cancer
Zsolt Toth, PhD (UF) ✓
Enrique Mesri, PhD (Sylvester)
Arun Srivastava, PhD (UF)
Anna Coghill, PhD, MPH (Moffitt)
- 3:40 p.m. – 4:30 p.m.** **Focused Session 1 – Infectious Disease (continued)** (Salon EF)
(20 minute discussion)
HPV
Susan T. Vadaparampil, PhD, MPH (Moffitt) ✓
Julia Seay, PhD (Sylvester)
Stephane Staras, PhD, MSPH (UF)
Jennifer Binning, PhD (Moffitt)

Florida Academic Cancer Center Alliance

Moffitt Cancer Center
Sylvester Comprehensive Cancer Center
University of Florida Health Cancer Center

2019 Annual Retreat

June 13, 2019 – June 14, 2019

JW Marriott Miami

1109 Brickell Avenue, 5th Floor **Contact:**
Priscilla Ochsendorf Pmo6@med.miami.edu
Office: (305) 243-4448 or Cell: (786) 317-4509

- 4:30 p.m. – 5:30 p.m.** **Focused Session 2 (Salon EF)**
(20 minute discussion) **Cancer Immunology & Immunotherapy – Present & Future**
Sri Gururangan, FRCP (Edin.) (UF) ✓
Krishna Komanduri, MD (Sylvester)
Catherine Flores, PhD (UF)
Daniel Abate-Daga, PhD (Moffitt)
- 5:30 p.m. – 7:00 p.m.** **Pilot Projects Poster Session / Cocktail Reception (Pre-Assembly Area)**
- 7:00 p.m. – 9:00 p.m.** **Dinner (Pre-Assembly Area)**

Friday, June 14, 2019 (All sessions will take place on the 5th Floor)

✓ = Moderator

- 7:45 a.m. – 8:15 a.m.** **Breakfast (Foyer outside Salon EFG)**
- 8:15 a.m. – 9:15 a.m.** **Focused Session 3 (Salon EF)**
(20 minute discussion) **Community Outreach and Engagement to Reduce Cancer Disparities**
Erin N. Kobetz, PhD (Sylvester) ✓
Diana Wilkie, PhD, RN, FAAN (UF)
Susan T. Vadaparampil, PhD, MPH (Moffitt)
- 9:15 a.m. – 10:15 a.m.** **Focused Session 4 (Salon EF)**
(20 minute discussion) **EMR – Based Patient Report Outcomes Monitoring, Management, and Cancer Care**
Brian D. Gonzalez, PhD (Moffitt) ✓
Frank J. Penedo, PhD (Sylvester)
Kea Turner, PhD, MPH (UF)
- 10:15 a.m. – 10:30 a.m.** **Break**
- 10:30 a.m. – 11:30 a.m.** **Breakout Sessions 3 – 6**
- 3. International Collaborations in Cancer Research (New York Room)**
Enrique Mesri, PhD (Sylvester) ✓
Folakemi Odedina, PhD (UF)
Tom Sellers, PhD, MPH (Moffitt)
- 4. Site Disease Focused – Breast (Madrid Room)**
Brian K. Law, PhD (UF) ✓
Joyce M. Slingerland, MD, PhD (Sylvester)
Brian Czerniecki, MD, PhD (Moffitt)
- 5. Site Disease Focused – Colon (Salon G)**
Ryan M. Thomas, MD, FACS (UF) ✓
David Robbins, MD (Sylvester)
Richard Kim, MD (Moffitt)
- 6. Site Disease Focused – Hematologic Malignancies (Salon EF)**
Eric Padron, MD (Moffitt) ✓
Krishna Komanduri, MD (Sylvester)
Olga Guryanova, MD, PhD (UF)

Florida Academic Cancer Center Alliance

Moffitt Cancer Center
Sylvester Comprehensive Cancer Center
University of Florida Health Cancer Center

2019 Annual Retreat

June 13, 2019 – June 14, 2019

JW Marriott Miami

1109 Brickell Avenue, 5th Floor **Contact:**
Priscilla Ochsendorf Pmo6@med.miami.edu
Office: (305) 243-4448 or Cell: (786) 317-4509

-
- 11:30 a.m. – 12:30 p.m.** **Focused Session 5** (*Salon EF*)
(20 minute discussion) **Cancer Survivorship and Patient Care Issues**
Frank J. Penedo, PhD (Sylvester) ✓
Youngmee Kim, PhD (Sylvester)
Smitha Pabbathi, MD (Moffitt)
- 12:30 p.m. – 1:30 p.m.** **Focused Session 6** (*Salon EF*)
(Working Lunch) **Shared Resources**
(20 minute discussion) Eric D. Wieder, PhD (Sylvester) ✓
Andria Doty, PhD (UF)
Brian Springer, MHA (Moffitt)
- 1:30 p.m.** **Closing Remarks** (*Salon EF*)
Stephen D. Nimer, MD (SCCC) ✓
Tom Sellers, PhD, MPH (Moffitt)
Jonathan D. Licht, MD (UF)
-

Mission:

To protect, promote & improve the health of all people in Florida through integrated state, county & community efforts.



Ron DeSantis
Governor

Scott A. Rivkees, MD
State Surgeon General

Vision: To be the Healthiest State in the Nation

July 1, 2020

Christopher R. Cogle, MD
Chair, Comprehensive Cancer Research Advisory Council
Health Bone Marrow Transplant - Shands Hospital
University of Florida
1515 SW Archer Road
Suite #100
Gainesville, Florida 32608

Dear Dr. Cogle:

I am pleased to transmit to you the Department of Health's Florida Consortium of National Cancer Institutes (NCI) Program report. This report, as indicated in section 381.915, Florida Statutes, includes information on age-adjusted cancer mortality, federal research funding being awarded to Florida institutions, and a status update on NCI center initiatives.

The Department of Health looks forward to our continued working relationship for reducing the burden of cancer in Florida. If you have any questions or would like additional copies, please contact Melissa Jordan, Interim Director, Division of Community Health Promotion, at 850-245-4577 or Melissa.Jordan@flhealth.gov

Sincerely,



Courtney F. Coppola
Chief of Staff

Enclosure